Document:

Exhibit 10.19

 

EXCLUSIVE LICENSE AGREEMENT FOR

LOWER EXTREMITY EXOSKELETON TECHNOLOGY

UC Case Numbers: B04-002, B05-045, B05-093,
B06-042;

US Patent App Numbers: 60/515,572;
10/976,652;60/645,417; 60/671,348

 

This license agreement (“AGREEMENT”)
is entered into as of the date that this AGREEMENT is fully executed by both parties (“EFFECTIVE DATE”), by
and between The Regents of the University of California, a California corporation, having its statewide administrative offices
at 1111 Franklin Street, 12th Floor, Oakland, California 94607-5200 acting through its Office of Technology Licensing,
at the University of California, Berkeley, having its administrative office at 2150 Shattuck Avenue, Suite 510, Berkeley, CA 94720-1620
(“REGENTS”), and Berkeley ExoTech, Inc., d/b/a Berkeley ExoWorks (“LICENSEE”),
a Delaware corporation, having a principal place of business at 63 Potomac Street, San Francisco, CA 94117.
The parties agree as follows:

 

1.           BACKGROUND

 

1.1           REGENTS
has an assignment of the intellectual property characterized as: (a) Lower Extremity Exoskeleton as described in REGENTS Case
Number B04-002 and PATENT RIGHTS that was invented by Homayoon Kazcrooni, Andrew Chu, Jean-Louis Racine and Adam Zoss, all employed
by the University of California, Berkeley at the time that the invention was made; (b) Lower Extremity Exoskeleton with Design
Improvements as described in REGENTS Case Number B05-045 and PATENT RIGHTS that was invented by Homayoon Kazcrooni, Nathan Harding
and Russdon Angold, all employed by the University of California, Berkeley at the time that the invention was made; (c) Lower Extremity
Exoskeleton that is Semi-Powered as described in REGENTS Case Number B05-093 and PATENT RIGHTS that was invented by Homayoon Kazcrooni,
Nathan Harding and Russdon Angold, all employed by the University of California, Berkeley at the time that the invention was made;
and (d) Power Regenerative Lower Extremity Prosthetic and Orthotic Systems as described in REGENTS Case Number B06-042 and PATENT
RIGHTS that was invented by Homayoon Kazcrooni, Nathan Harding and Russdon Angold, all employed by the University of California,
Berkeley at the time that the invention was made (collectively “INVENTIONS”).

 

1.2           LICENSEE
entered into a letter agreement (“PREVIOUS AGREEMENT”) with REGENTS that was effective as of 2005 March 17
and terminates on 2005 September 17, for the purpose of granting LICENSEE an exclusive right to negotiate an option or exclusive
license in PATENT RIGHTS.

 

1.3           LICENSEE
provided REGENTS with a marketing overview and financial forecasts for the commercialization of the INVENTIONS in order to evaluate
LICENSEE’s capabilities as a LICENSEE.

 

    	Page 1 of 28

    	 

    

 

1.4           In
accordance with Paragraph 3.3 of this AGREEMENT, the development of the INVENTIONS was sponsored in part by various grants
from U.S. Government agencies, and as a consequence, REGENTS elected to retain title to the INVENTIONS subject to the rights and
regulations of the U.S. Government under 35 USC 200-212 and implementing regulations, including REGENT’s grant back to the
U.S. Government of a non-exclusive, non-transferable, irrevocable, paid-up license to practice or have practiced the INVENTIONS
for or on behalf of the U.S. Government throughout the world. These U.S. Government grants are DARPA Contract No. DAD19-01-1-0509.
The LICENSEE asked REGENTS about how to handle royalties when LICENSEE SELLS its products to customers that in turn reSELL the
products to the U.S. Government; and REGENTS responded that in accordance with Paragraph 6.7 of this AGREEMENT, LICENSEE does not
pay a royalty to REGENTS (and reduce the amount charged for LICENSED PRODUCT by an amount equal to the royalty for such LICENSED
PRODUCT otherwise due REGENTS) when either (a) LICENSEE’s customers indicate that the products SOLD will be reSOLD to the
U.S. Government, or (b) LICENSEE knows or has reason to know that the products SOLD will be reSOLD to the U.S. Government.

 

1.5           LICENSEE
requested certain rights from REGENTS to commercialize the INVENTIONS.

 

1.6           REGENTS
wishes to respond to the request of the LICENSEE by granting the following rights to the LICENSEE to enable the general public
to enjoy the products and other benefits derived from the INVENTION.

 

2.           DEFINITIONS

 

As used in this AGREEMENT, the following
terms, whether used in the singular or plural, have the following meanings:

 

2.1           “PATENT
RIGHTS” means the PATENT CLAIMS of, to the extent assigned to or otherwise obtained by REGENTS, (a) the U.S. patents
and patent applications, (b) the corresponding foreign patents and patent applications, and (c) any reissues, extensions, substitutions,
continuations, divisions, and continuation-in-part applications (but only those PATENT CLAIMS in the continuation-in-part applications
that are entirely supported in the specification and entitled to the priority date of the parent application) that are based on
the following patents and patent applications: Serial Numbers 60/515,572 (B04-002-1), entitled Lower Extremity Enhancer, filed
on 2003 October 29 by Homayoon Kazcrooni, Jean-Louis Racine, Andrew Chu and Adam Zoss; 10/976,652 (B04-002-2), entitled Lower Extremity
Enhancer, filed on 2004 October 29 by Homayoon Kazcrooni, Jean-Louis Racine, Andrew Chu and Adam Zoss; 60/645,417 (B05-045-1),
entitled Lower Extremity Exoskeleton, filed on 2005 January 18 by Homayoon Kazcrooni, Nathan H. Harding and Russdon Angold; and
60/671,348 (B05-093-1), entitled Semi-Powered Lower Extremity Exoskeleton, filed on 2005 April 13 by Homayoon Kazcrooni, Nathan
H. Harding and Russdon Angold. This definition of PATENT RIGHTS excludes any rights in and to NEW DEVELOPMENTS.

 

2.2           “PATENT
CLAIM” means a claim of a patent or patent application in any country that (a) has not expired; (b) has not been disclaimed;
(c) has not been cancelled or superseded, or if cancelled or superseded, has been reinstated; and (d) has not been revoked, held
invalid, or otherwise declared unenforceable or not allowable by a tribunal or patent authority of competent jurisdiction over
such claim in such country from which no further appeal has or may be taken.

 

    	Page 2 of 28

    	 

    

 

 

2.3           “NEW
DEVELOPMENT” means inventions, or claims to inventions, which constitute advancements, developments, or improvements,
whether or not patentable and whether or not the subject of any patent application, but if patentable, are not sufficiently supported
by the specification of a previously-filed patent or patent application within the PATENT RIGHTS to be entitled to the priority
date of the previously-filed patent or patent application.

 

2.4           “LICENSED
PRODUCT” means any product, service, kit, material, or apparatus the manufacture, use, SALE, offer for SALE, distribution,
or import of which, in the absence of the license granted in this AGREEMENT, would infringe, or contribute to, or induce the infringement
of, any PATENT RIGHTS were they issued in a country at the time of the infringing activity in that country.

 

2.5           “LICENSED
METHOD” means any process, service or method the use or practice of which, in the absence of the license granted in this
AGREEMENT, would infringe, or contribute to, or induce the infringement of any PATENT RIGHTS were they issued in a country at the
time of the infringing activity in that country.

 

2.6           “LICENSED
FIELD-OF-USE” means the following applications or markets: all applications and markets without limitation (“UNRESTRICTED”)
for the first five (5) years after EFFECTIVE DATE, and thereafter if LICENSEE SELLS LICENSED PRODUCT for use in non-military applications
within five years after EFFECTIVE DATE, the LICENSED FIELD-OF-USE remains UNRESTRICTED, otherwise LICENSED FIELD-OF-USE is military
applications and markets.

 

2.7           “LICENSED
TERRITORY” means jurisdictions where REGENTS has obtained, or obtains PATENT RIGHTS, or filed corresponding patent applications
under PATENT RIGHTS.

 

2.8           “SUBLICENSEE”
means the third parties, AFFILIATES or JOINT VENTURES that, to the extent allowable by this AGREEMENT, are granted a sublicense
by LICENSEE to practice LICENSED METHOD, or to make, have made, use, SELL, offer for SALE, distribute or import LICENSED PRODUCT.

 

2.9           “SALE”
means the act of selling leasing or otherwise transferring, providing, exploiting or furnishing for use for any consideration.
Correspondingly, “SELL” means to make a SALE or cause a SALE to be made, and “SOLD” means
to have made a SALE or caused a SALE to have been made.

 

2.10         “COMBINATION
LICENSED PRODUCT” means a LICENSED PRODUCT that is a combination of one or more LICENSED PRODUCTS with one or more products
that are not LICENSED PRODUCTS (“NLPs”) where the combination is packaged and SOLD together to a purchaser for
a single price and where the purchaser can remove the LICENSED PRODUCT from the NLP and use the NLP alone, and either of the following:

 

2.10a   the removal and usage
is obvious to the purchaser from the design or operation of the combination; or

 

    	Page 3 of 28

    	 

    

 

 

2.10b   the removal and usage
is described in the packaging, literature or documentation accompanying the combination.

 

2.11        “NET
INVOICE PRICE” means (a) the gross invoice price charged and the value of any other consideration received for a SALE
of a LICENSED PRODUCT or the performance of a LICENSE METHOD when SOLD or performed by LICENSEE, (b) the gross invoice price charged
and the value of any other consideration received for a SALE of a LICENSED PRODUCT or the performance of a LICENSE METHOD when
SOLD or performed by SUBLICENSEE, and in the above cases, less the following items, but only to the extent that they actually pertain
to the disposition of LICENSED PRODUCT, LICENSED METHOD, COMBINATION LICENSED PRODUCT, or both, and are separately billed:

 

2.11a   Allowances actually granted
to customers for rejections, returns, prompt payment or volume discounts;

 

2.11b   Freight, transport packing,
or insurance charges associated with transportation;

 

2.11c   Taxes, including DEDUCTIBLE
VALUE-ADDED TAX, tariffs or import/export duties based on SALES when included in the gross invoice price, but excluding value-added
taxes other than DEDUCTIBLE VALUE-ADDED TAX or taxes assessed on income derived from SALES. “DEDUCTIBLE VALUE-ADDED TAX”
means value-added tax only to the extent that such value-added tax is actually incurred and is not reimbursable, refundable, or
creditable under the tax authority of any country;

 

2.11d   Discounts or rebates
paid or credited to customers, third-party payers, health-care systems, or administrators solely to promote the inclusion of LICENSED
PRODUCT in formulary programs;

 

2.11e   Wholesaler’s discounts
or rebates to customers, third-party payers, health-care systems, or administrators solely to promote the inclusion of LICENSED
PRODUCT in formulary programs; and

 

2.11f   Rebates or discounts paid
or credited pursuant to applicable law.

 

2.12        “NET
SALES PRICE” means the NET INVOICE PRICE except in the instances described as follows:

 

2.12a   In those instances where
LICENSED PRODUCT, or LICENSED METHOD is not SOLD, but is otherwise exploited, the NET SALES PRICE for the purpose of computing
royalties for LICENSED PRODUCT and LICENSED METHOD are determined as follows:

 

i.            If
LICENSEE and/or any SUBLICENSEE are currently offering for SALE products or services that are the same or similar to LICENSED PRODUCT
or LICENSED METHOD, then the NET SALES PRICE for LICENSED PRODUCT or LICENSED METHOD otherwise exploited is the NET INVOICE PRICE
of products or services of the same or similar kind and quality, SOLD in similar quantities, currently being offered for SALE by
the LICENSEE and/or any SUBLICENSEE; or

 

    	Page 4 of 28

    	 

    

 

ii.         If
LICENSEE and/or any SUBLICENSEE are not currently offering for SALE products or services that are the same or similar to
LICENSED PRODUCT or LICENSED METHOD, then NET SALES PRICE for a LICENSED PRODUCT or LICENSED METHOD otherwise exploited, is the
average NET INVOICE PRICE at which products or services of the same or similar kind and quality, SOLD in similar quantities, are
currently being offered for SALE by other manufacturers; or

 

iii.         If
LICENSEE, SUBLICENSEE and/or any other companies are not currently offering for SALE products or services that are the same
or similar to LICENSED PRODUCT or LICENSED METHOD, then NET SALES PRICE for a LICENSED PRODUCT or LICENSED METHOD otherwise exploited,
is the LICENSEE’s and/or any SUBLICENSEE’s costs of manufacture of LICENSED PRODUCT or costs of performing LICENSED
METHOD, determined by the customary accounting procedures of the LICENSEE and/or any SUBLICENSEE, plus one-hundred percent (100%)
of those costs.

 

2.12b   Sales of COMBINATION
LICENSED PRODUCTS: The applicable NET SALES PRICE for any COMBINATION LICENSED PRODUCT will be calculated by:

 

i.            Multiplying
the NET INVOICE PRICE of the COMBINATION LICENSED PRODUCT by the ratio of the average NET INVOICE PRICE of the LICENSED PRODUCT
included in the combination (during the six-month period in which such combination SALE occurred) to the sum of the average NET
INVOICE PRICE of each of the LICENSED PRODUCT and the NLPs included in the combination (during the six-month period in which such
combination SALE occurred); or

 

ii.           If
an item included in the combination is not offered for SALE by LICENSEE, then

 

a.           The
NET INVOICE PRICE of the item will equal the average NET INVOICE PRICE at which products of the same or similar kind and quality,
sold in similar quantities, are offered for SALE by other manufacturers (during the six months in which such combination SALE occurred)
to the extent such information is readily available to LICENSEE; or

 

b.           If
the items are not offered for SALE by LICENSEE or any other company or cannot be reasonably ascertained by LICENSEE, then the NET
INVOICE PRICE of the item will equal LICENSEE’s cost of goods sold (“COGS”) related to the manufacture
of the item as determined by the customary accounting procedures of LICENSEE.

 

    	Page 5 of 28

    	 

    

 

2.12c   For a REACQUISITION SALE
OR EXPLOITATION, the NET SALES PRICE means the NET INVOICE PRICE upon the SALE of LICENSED PRODUCT or LICENSED METHOD by LICENSEE
or SUBLICENSEE. “REACQUISITION SALE OR EXPLOITATION” means those instances where the LICENSEE or a SUBLICENSEE
acquires LICENSED PRODUCT or LICENSED METHOD and then subsequently SELLS such LICENSED PRODUCT or LICENSED METHOD;

 

2.12d   For any RELATIONSHIP-INFLUENCED
SALE of LICENSED PRODUCT or LICENSED METHOD, the NET SALES will be based on the NET INVOICE PRICE at which the RELATIONSHIP-INFLUENCED
SALE PURCHASER resells LICENSED PRODUCT. “RELATIONSHIP-INFLUENCED SALE” means a SALE of LICENSED PRODUCT or
LICENSED METHOD, between LICENSEE and any SUBLICENSEE or between LICENSEE and/or SUBLICENSEE and an AFFILIATE, a JOINT VENTURE,
or a RELATED PARTY, “RELATIONSHIP-INFLUENCED SALE PURCHASER” means the purchaser of LICENSED PRODUCT or LICENSED
METHOD in a RELATIONSHIP-INFLUENCED SALE.

 

2.13         “AFFILIATE”
means any entity that, directly or indirectly, CONTROLS LICENSEE, is CONTROLLED by LICENSEE, or is under common CONTROL with LICENSEE,
“CONTROL” means as follows: (a) having the actual, present capacity to elect a majority of the directors of
such affiliate; (b) having the power to direct at least forty percent (40%) of the voting rights entitled to elect directors; or
(c) in any country where the local law will not permit foreign equity participation of a majority, then ownership or control, directly
or indirectly, of the maximum percentage of such outstanding stock or voting rights permitted by local law.

 

2.14         “JOINT
VENTURE” means any separate entity established pursuant to an agreement between a third party and LICENSEE and/or SUBLICENSEE
to constitute a vehicle for a joint venture, in which the separate entity manufactures, uses, purchases, SELLS, or acquires LICENSED
PRODUCT or LICENSED METHOD from LICENSEE and/or SUBLICENSEE.

 

2.15         “RELATED
PARTY” means a corporation, firm, or other entity with which, or individual with whom, LICENSEE and/or any SUBLICENSEE
(or any of their respective stockholders, subsidiaries or AFFILIATES) have an agreement, understanding, or arrangement (for example,
an agreement providing LICENSEE and/or SUBLICENSEE with an option to purchase stock or equity interest, or a share of revenue or
profits) that (a) is unrelated to the SALE of LICENSED PRODUCT or LICENSED METHOD and without which such other agreement, understanding,
or arrangement, the amounts, if any, charged by LICENSEE or SUBLICENSEE to such entity or individual for LICENSED PRODUCT, would
be higher than the NET INVOICE PRICE actually received, or (b) if such agreement, understanding, or arrangement results in LICENSEE
or SUBLICENSEE extending to such entity or individual lower prices for LICENSED PRODUCT or LICENSED METHOD than those charged to
others without such agreement, understanding, or arrangement buying similar products or services in similar quantities.

 

    	Page 6 of 28

    	 

    

 

 

2.16        “CURRENT
CAPITALIZATION” means all the shares of outstanding Common Stock, consisting of 0 shares, all shares of outstanding Preferred
Stock, consisting of 0 shares, and all shares of Common Stock authorized for issuance to employees, consultants and directors pursuant
to the LICENSEE’s Stock Purchase Agreements, of which 776,000 are authorized.

 

3.           GRANT
OF LICENSE

 

3.1          Licensee
Grant: Subject to the limitations set forth in this AGREEMENT, including the license granted to the U.S. Government and rights
reserved for REGENTS as well as other educational and nonprofit institutions, REGENTS hereby grants to LICENSEE an exclusive license
under PATENT RIGHTS to make, have made, use, SELL, offer for SALE, distribute and import LICENSED PRODUCT and to practice LICENSED
METHOD in LICENSED TERRITORY in LICENSED FIELD-OF-USE, with LICENSED FIELD-OF-USE is subject to modification as specified in
Paragraph 2.6.

 

3.2          Reserved
Rights: REGENTS expressly reserves the rights to (a) publish any and all technical data resulting from any research performed
by REGENTS relating to the INVENTIONS, (b) make and use the INVENTIONS and related technology for educational and research purposes,
(c) disseminate tangible materials associated with, or required to practice the INVENTIONS and/or PATENT RIGHTS to researchers
at nonprofit institutions for educational and research purposes, and (d) allow other educational and nonprofit institutions to
make and use the INVENTIONS and related technology for educational and research purposes only.

 

3.3          Government
Obligations: The licenses granted in this AGREEMENT are subject to the overriding obligations to the U.S. Government including:

 

3.3a   In accordance with 35
USC §200-212 and implementing regulations, REGENTS has granted back to the U.S. Government a non-exclusive, non-transferable,
irrevocable, paid-up license to practice or have practiced INVENTIONS for or on behalf of the U.S. Government throughout the world;

 

3.3b   In accordance with 37
CFR §401.14(h), REGENTS has an obligation to report on the utilization of the INVENTIONS; and in order to fulfill this obligation,
LICENSEE has a continuing responsibility to keep REGENTS informed of the large/small entity status (as defined in 15 USC §632)
of LICENSEE and its SUBLICENSEES;

 

3.3c   In accordance with PL
96-517 as amended by PL 98-620, to the extent required by law or regulation, LICENSED PRODUCT that is exclusively SOLD in the U.S.
will be substantially manufactured in the US.

 

4.           GRANT
OF SUBLICENSES

 

4.1          Sublicense
Grant: REGENTS hereby grants to LICENSEE the right to issue sublicenses to SUBLICENSEES to make, have made, use, SELL, offer
for SALE, distribute or import LICENSED PRODUCT and to practice the LICENSED METHOD in LICENSED FIELD-OF-USE in LICENSED TERRITORY,
provided that LICENSEE has exclusive rights in the LICENSED FIELD-OF-USE (with modification as specified in Paragraph 2.6)
under this AGREEMENT on the effective date of the sublicense agreement. For the avoidance of doubt, AFFILIATES and JOINT VENTURES
do not have licenses under the PATENT RIGHTS unless such AFFILIATES and JOINT VENTURES are granted a sublicense.

 

    	Page 7 of 28

    	 

    

 

4.2          Terms:
To the extent applicable, all sublicensees will include all of the rights of, and will require the performance of all the obligations
due to REGENTS and, if applicable, to the U.S. Government, that are contained in this AGREEMENT, including, but not limited to,
at least the following terms:

 

4.2a   A statement setting forth
the date upon which LICENSEE’s exclusive rights, privileges, and license hereunder will expire;

 

4.2b   The same provision for
indemnification of REGENTS as has been provided for in this AGREEMENT;

 

4.2c   A statement such that,
to the extent applicable, the obligations of this AGREEMENT will be binding upon the SUBLICENSEE as if it were n place of LICENSEE,
except as follows:

 

i.          EARNED
ROYALTY rates and MINIMUM ANNUAL ROYALTIES may be higher than those specified in this AGREEMENT; and

 

ii.         SUBLICENSEES
will be precluded from granting further sublicenses unless agreed to in writing by REGENTS.

 

4.3          Notification:
LICENSEE will notify REGENTS of each sublicense granted pursuant to this AGREEMENT, and furnish to REGENTS a summary of the material
terms of each sublicense agreement.

 

4.4          Responsibilities:
For purposes of this AGREEMENT, the operations of all SUBLICENSEES are deemed to be the operations of LICENSEE, for which LICENSEE
is responsible. Also, LICENSEE will guarantee and deliver the payment of all monies due REGENTS from SUBLICENSEES; and LICENSEE
will collect and deliver all reports due REGENTS from SUBLICENSEES.

 

4.5          Termination:
Upon termination of this AGREEMENT for any reason, REGENTS, at its sole discretion, will determine whether any or all sublicenses
that are granted pursuant to this AGREEMENT will be canceled or remain in effect and assigned to REGENTS, but if REGENTS opts to
assign sublicenses to REGENTS, then REGENTS will not be bound to perform any duties or obligations set forth in any such sublicenses
that extend beyond the duties and obligations of REGENTS as set forth in this AGREEMENT.

 

4.6          Sublicense
Fees: LICENSEE will pay to REGENTS one percent (1%) of any cash and of the cash equivalent of other consideration owed
to LICENSEE for the grant of rights under each sublicense agreement in addition to all other payments by LICENSEE to REGENTS as
specified in this AGREEMENT including EARNED ROYALTIES as specified in Paragraph 6.2 of this AGREEMENT.

 

    	Page 8 of 28

    	 

    

 

4.7          Comprehensive
Commercialization: If REGENTS (to the extent of the actual knowledge of the licensing professional responsible for administrating
this AGREEMENT) or a third party discovers that the INVENTIONS are useful for an application covered by the LICENSED FIELD-OF-USE,
but for which LICENSEE and its SUBLICENSEES have not developed or are not currently developing LICENSED PRODUCT or LICENSED METHOD
(“NEW APPLICATION”), then:

 

4.7a   REGENTS may give written
notice to LICENSEE identifying the NEW APPLICATION, except for the following: (a) information that is subject to restrictions of
confidentiality with third parties, or (b) information that originates with REGENTS personnel who do not assent to its disclosure
to LICENSEE. If REGENTS gives such written notice to LICENSEE, then LICENSEE will have ninety (90) days to give REGENTS written
notice stating whether LICENSEE elects to develop LICENSED PRODUCT or LICENSED METHOD for the application;

 

4.7b   If LICENSEE elects to
develop and commercialize LICENSED PRODUCT or LICENSED METHOD for the NEW APPLICATION, then LICENSEE will submit a commercialization
plan with performance milestones and PROGESS REPORT to REGENTS in accordance with the Progress Report Article of this AGREEMENT;

 

4.7c   If LICENSEE elects not
to develop and commercialize LICENSED PRODUCT or LICENSED METHOD for the NEW APPLICATION, then REGENTS may seek third parties to
develop and commercialize LICENSED PRODUCT or LICENSED METHOD for the NEW APPLICATION. If REGENTS is successful in finding a third
party, it will refer such third party to LICENSEE. If the third party requests a sublicense under this AGREEMENT, then LICENSEE
will report the request to REGENTS within thirty (30) days from the date of such request:

 

i.          If
such request results in a sublicense, then LICENSEE will report it to REGENTS in accordance with this AGREEMENT;

 

ii.         If
LICENSEE has not granted a sublicense to the third party within six (6) months after receiving such request, then within thirty
(30) days after such refusal, LICENSEE will submit to REGENTS a report specifying the license terms proposed by the third party
and a written justification for LICENSEE’s refusal to grant the proposed sublicense. If REGENTS, at its sole discretion,
determines that the terms of the sublicense proposed by the third party are reasonable under the totality of the circumstances,
taking into account LICENSEE’s LICENSED PRODUCTS or LICENSED METHOD in development, then REGENTS will have the right to grant
to the third party a license to make, have made, use, SELL, offer for SALE, distribute and import LICENSED PRODUCTS or LICENSED
METHOD for use in the LICENSED FIELD-OF-USE at substantially the same terms most recently proposed to LICENSEE by that the third
party and providing royalty rates that are at least equal to those paid by LICENSEE.

 

    	Page 9 of 28

    	 

    

 

5.           FEES

 

5.1          Issue
Fee: As partial consideration for all rights and licenses granted by REGENTS to LICENSEE herein, LICENSEE will pay to REGENTS
a license issue fee of five thousand dollars ($5,000) due and payable at execution of this AGREEMENT.

 

5.2          Equity:
As partial consideration for all rights and licenses granted by REGENTS to LICENSEE herein, and based upon the CURRENT CAPITALIZATION,
LICENSEE will provide and deliver to REGENTS 31,040 shares of its Common Stock (“EQUITY”) representing
four percent (4%) of CURRENT CAPITALIZATION in accordance with the terms of a Shareholder’s Agreement by and between
REGENTS and LICENSEE. This Shareholder’s Agreement is subject to approval by REGENTS, and if this approval is not received,
then the parties will negotiate alternate consideration. Within 30 days after execution by REGENTS of this Shareholder’s
Agreement, LICENSEE will deliver the EQUITY to REGENTS. Also, as REGENTS holds any EQUITY, LICENSEE will grant REGENTS observer
rights during LICENSEE’s Board of Director meetings.

 

5.3          Fee
Notes: The license issue fee is not refundable, not creditable, and not an advance against any other payments by LICENSEE to
REGENTS pursuant to this AGREEMENT.

 

6.           ROYALTIES

 

6.1          Applicability:
EARNED ROYALTIES will be payable on LICENSED PRODUCT and LICENSED METHOD covered by PATENT RIGHTS.

 

6.2          Rate:
As further consideration for all LICENSEE’s rights and licenses granted herein, LICENSEE will pay to REGENTS an earned royalty
based on the NET SALES PRICE (“EARNED ROYALTY”) at the rate of one percent (1%) based on the NET SALES
PRICE of LICENSED PRODUCT or LICENSED METHOD.

 

6.3          Schedule:
EARNED ROYALTIES accruing to REGENTS will be paid to REGENTS semi-annually on or before the following dates of each calendar year:

 

		·	February 28 for the calendar six months ending December 31

 

		·	August 31 for the calendar six months ending June 30

 

6.4          Minimum
Annual Royalty: LICENSEE will pay to REGENTS a minimum annual royalty in the amounts as set forth below, by February 28 of
the calendar year in which payment is due, and each payment will be credited against the EARNED ROYALTY due and owing for the calendar
year in which each payment is made.

 

		·	Beginning in the first calendar year after the first occurrence of NET SALES PRICE that is royalty bearing (in other words,
not SOLD or reSOLD to the U.S. Government):

 

		·	Next calendar year:     $5,000

 

    	Page 10 of 28

    	 

    

 

		·	Next calendar year:     $7,500

 

		·	Next calendar year:     $10,000

 

		·	Next calendar year:     $12,500

 

		·	Every calendar year thereafter: $15,000 but subject to the following:

 

6.4a   If LICENSEE does not
SELL LICENSED PRODUCT or LICENSED METHOD for use in non-military applications within five (5) years after EFFECTIVE DATE, then
LICENSEE’s LICENSED FIELD-OF-USE will be modified as specified in Paragraph 2.6, and minimum annual royalties will remain
as specified above; or

 

6.4b   If LICENSEE does SELL
LICENSED PRODUCT or LICENSED METHOD for use in non-military applications within five (5) years after EFFECTIVE DATE, then LICENSEE’s
minimum annual royalties will increase as follows:

 

		·	In the calendar year following the calendar year in which minimum annual royalty is $12,500:    $15,000

 

		·	Next calendar year:      $20,000

 

		·	Every calendar year thereafter:      $25,000

 

6.5          Sales
Outside US:

 

6.5a   Charges: EARNED ROYALTIES
on NET SALES PRICE received in any country outside the U.S. will not be reduced by any taxes, fees, or other charges imposed by
the government of such country except those taxes, fees, and charges allowed under the provision of the Definition of NET SALES
PRICE as described in this AGREEMENT. LICENSEE also will be responsible for all bank transfer charges;

 

6.5b   Conversion: When LICENSED
PRODUCT or LICENSED METHOD is SOLD for monies other than U.S. dollars, the EARNED ROYALTIES and any other consideration due to
REGENTS will first be determined in the foreign currency of the country in which such LICENSED PRODUCTS or LICENSED METHOD were
SOLD or other consideration was received and then converted into equivalent U.S. dollars. The exchange rate will be the average
exchange rate quoted in the Wall Street Journal during the last thirty (30) days of the reporting period.

 

6.6          Patent
Expiration or Termination: In the event that any patent, patent application, or any claim thereof included within PATENT RIGHTS
expires or is held invalid in a final decision by a court of competent jurisdiction and last resort and from which no appeal has
or can be taken, all obligation to pay royalties based on such patent, patent application, or claim or any claim patentably indistinct
therefrom will cease as of the date of such final decision. However, LICENSEE is not relieved from paying any royalties that accrued
before such final decision, and LICENSEE is obligated to pay the full amount of royalties due hereunder.

 

    	Page 11 of 28

    	 

    

 

6.7          U.S.
Government Obligation: No royalties will be paid or collected on LICENSED PRODUCT or LICENSED METHOD distributed to or used
by the U.S. Government. LICENSEE and its SUBLICENSEES agree to reduce the amount charged for LICENSED PRODUCT or LICENSED METHOD
distributed to the U.S. Government by an amount equal to the royalty for such LICENSED PRODUCT or LICENSED METHOD otherwise due
REGENTS.

 

7.          DUE
DILIGENCE

 

7.1           Obligation:
Upon execution of this AGREEMENT, LICENSEE will diligently proceed with the development, manufacture, government approval, marketing
and SALE of LICENSED PRODUCT or LICENSED METHOD in quantities sufficient to meet the market demands.

 

7.2           Performance
Metrics: LICENSEE specifically commits, in accordance with the obligation stated in paragraph 7.1 to achieving the following
objectives:

 

		·	By 2006 March 31: First beta unit shipped to a potential customer

 

		·	By 2006 December 31: First commercial order

 

		·	By 2007 June 30: First commercial shipment

 

7.3          Failure
to Perform: If LICENSEE is unable to meet any of its due diligence obligations as set forth in the Paragraph above, then REGENTS
may notify LICENSEE of its failure to perform.

 

7.3a   If REGENTS gives such
written notice to LICENSEE, then LICENSEE may extend the target date of any diligence obligation for an additional six (6) months
upon payment to REGENTS of an additional $5,000. Additional extensions may be granted only by mutual written agreement of the parties
to this AGREEMENT. Such extension fees are in addition to all other payments by LICENSEE to REGENTS pursuant to this AGREEMENT;

 

7.3b   If LICENSEE opts not to
extend the obligation or fails to meet it by the extended target date, then REGENTS will have the right and option either to terminate
this AGREEMENT or to reduce LICENSEE’s exclusive license to a non-exclusive, royalty-bearing license. To exercise either
the right to terminate this AGREEMENT or to reduce the license to a non-exclusive license for lack of diligence as specified in
this Due Diligence Article, REGENTS will give LICENSEE written notice of the deficiency. After receiving notice, LICNESEE will
have sixty (60) days to cure the deficiency or to request arbitration. If REGENTS has not received a written request for arbitration
or satisfactory tangible evidence that the deficiency has been cured by the end of the sixty (60)-day period, then REGENTS may,
at its option, either terminate the AGREEMENT or reduce LICENSEE’s exclusive license to a non-exclusive license by giving
written notice to LICENSEE;

 

    	Page 12 of 28

    	 

    

 

7.3c   This right to terminate
the AGREEMENT or reduce LICENSEE’s exclusive license to a non-exclusive license, if exercised will (a) supersede the rights
granted in Grant of License Article in this AGREEMENT, and (b) be REGENTS’ sole remedy for breach of due diligence obligations.

 

7.4          Arbitration:
At the request of either party, any controversy or claim arising out of or relating to the diligence provisions of this Due Diligence
Article will be settled by arbitration conducted in San Francisco, CA in accordance with the then current Licensing Agreement Arbitration
Rules of the American Arbitration Association. Judgment upon the award rendered by the arbitrator(s) will be binding on the parties
and may be entered by either party in the court or forum having jurisdiction. In determination of due diligence, the arbitrator
may determine solely the issues of fact or law with respect to termination of LICENSEE’s rights under this AGREEMENT but
will not have the authority to award monetary damages or grant equitable relief.

 

8.           COMMERCIALIZATION,
PROGRESS AND ROYALTY REPORTS

 

8.1          Report
of Commercialization Plan: LICENSEE represents that the marketing overview and financial forecast provided to REGENTS are,
as of the EFFECTIVE DATE of this AGREEMENT, consistent with the equivalent information contained in LICENSEE’s business plan
that LICENSEE has presented to its Board of Directors and to entities that have or may invest capital in LICENSEE.

 

8.2          Progress
Reports: In order to enable REGENTS to access LICENSEE’s general progress on the development of LICENSED PRODUCT and
LICENSED METHOD and also determine whether or not LICENSEE has met its diligence obligations as set forth in this AGREEMENT, beginning
on February 28 in the year following the year in which this AGREEMENT is executed, and semi-annually thereafter until the first
SALE of each LICENSED PRODUCT or LICENSED METHOD, LICENSEE will submit to REGENTS a progress report as described hereunder covering
activities by LICENSESE and its SUBLICENSEES related to the development, testing, government approval, and marketing of all LICENSED
PRODUCT and LICENSED METHOD (“PROGRESS REPORT”).

 

8.3          Contents
of Progress Reports: Each PROGRESS REPORT submitted by LICENSEE to REGENTS will include, but is not limited to, a detailed
summary of the following topics:

 

		·	Summary of work completed and in progress;

 

		·	Summary of actual and anticipated events and milestones;

 

		·	The date of first SALE, if any, of LICENSED PRODUCT or LICENSED METHOD; and

 

		·	Activities of SUBLICENSEES if any, including any change in their large/small entity status (as defined in 15 USC §632).

 

    	Page 13 of 28

    	 

    

 

8.4          Royalty
Reports: After the first SALE of LICENSED PRODUCT or LICENSED METHOD, LICENSEE will provide semi-annually royalty reports (“ROYALTY
REPORT”) to REGENTS on or before each February 28 and August 31 of each year.

 

8.5          Contents
of Royalty Reports: Each such ROYALTY REPORT will cover the most recently completed calendar quarter (October through December,
January through March, April through June, and July through September) and will include, but not be limited to, the following:

 

8.5a   Pricing: The gross
invoice prices of LICENSED PRODUCT or LICENSED METHOD that are SOLD by LICENSEE and its SUBLICENSEES;

 

8.5b   Revenue: NET SALES
PRICE of LICENSED PRODUCT or LICENSED METHOD that are SOLD by LICENSEE and its SUBLICENSEES;

 

8.5c   Volume: The quantity
of LICENSED PRODUCT or LICENSED METHOD manufactured and SOLD by LICENSEE and its SUBLICENSEES;

 

8.5d   Royalty: The EARNED
ROYALTIES due REGENTS, in U.S. dollars, payable hereunder with respect to NET SALES PRICE of LICENSEE and its SUBLICENSEES;

 

8.5e   Calculations: The
method used to calculate EARNED ROYALTY, specifying all deductions taken and the dollar amount of each such deduction as well as
the exchange rates used, if any;

 

8.5f   Non-cash Consideration:
The amount of the cash and the amount of the cash equivalent of the non-cash consideration as provided for in this AGREEMENT, including
the method used to calculate the non-cash consideration; and

 

8.5g   Sublicenses: The
name and address of new SUBLICENSEES and their large/small entity status (as defined by 15 USC §632) along with a summary
of the material terms of each new sublicensing agreement consummated.

 

8.6          No
Sale: If LICENSED PRODUCT or LICENSED METHOD have not been SOLD during any reporting period after the first SALE of LICENSED
PRODUCT or LICENSED METHOD, then the ROYALTY REPORT for that reporting period will contain a statement to this effect.

 

9.           BOOKS
AND RECORDS

 

9.1          Obligation:
LICENSEE will keep books and records accurately showing all payment due to REGENTS and all LICENSED PRODUCT or LICENSED METHOD
manufactured, used, SOLD, offered for SALE, distributed, imported, and/or otherwise exploited under the terms of this AGREEMENT.
Such books and records will be preserved for at least five (5) years after the date of the payment to which they pertain and will
be open to examination by representatives or agents of REGENTS at reasonable times to determine their accuracy and assess the LICENSEE’S
compliance with the terms of this AGREEMENT.

 

    	Page 14 of 28

    	 

    

 

9.2          Costs.
The fees and expenses of representatives of REGENTS that perform the examination will be borne by REGENTS. However, if an error
in royalties of more than five percent (5%) of the total royalties due for any year is discovered or any other material term of
this AGREEMENT is discovered to have been breached, then LICENSEE will bear the cost of the examination. LICENSEE will remit any
underpayment to REGENTS within thirty (30) days of the examination result.

 

10.         LIFE
OF THE AGREEMENT

 

10.1        Duration:
Unless otherwise terminated by operation of law or by acts of the parties in accordance with the terms of this AGREEMENT, this
AGREEMENT will remain in effect in each country from the EFFECTIVE DATE until the expiration or abandonment of the last of the
PATENT RIGHTS licensed hereunder in such country.

 

10.2        Surviving
Rights. Any termination or expiration of this AGREEMENT will not affect the rights and obligations set forth in the following
Paragraphs and Articles of this AGREEMENT:

 

		·	Article 2                  Definition

 

		·	Article 4                  Grant of Sublicenses

 

		·	Article 9                  Books and Records

 

		·	Article 10                Life of Agreement

 

		·	Article 12                Disposition of Products

 

		·	Paragraphs 14.6 and 14.7 Patent Prosecution and Maintenance

 

		·	Article 16                Limited Warranty

 

		·	Article 17                Limitation on Liability

 

		·	Article 18                Indemnification

 

		·	Article 19                Confidentiality

 

		·	Article 20                Notices

 

		·	Paragraph 21.3       Late Payments

 

		·	Article 22                Governing Laws, Venue and Attorneys’
Fees

 

		·	Paragraph 25.1       Use of Names and Trademarks

 

    	Page 15 of 28

    	 

    

 

10.3         No
Relief: The termination or expiration of this AGREEMENT (a) will not relieve LICENSEE of its obligation to make any payments
pursuant to this AGREEMENT that are owed to REGENTS at the time of such termination or expiration, (b) will not impair any accrued
right of REGENTS including the right to receive EARNED ROYALTIES and other fees in accordance with this AGREEMENT, and (c) will
not relieve any obligation, of either party to the other party, that was established prior to such termination or expiration.

 

10.4         Bankruptcy:
This AGREEMENT will automatically terminate without the obligation to provide any notice as set forth in this AGREEMENT upon the
filing of a petition for relief under the U.S. Bankruptcy Code by or against the LICENSEE as a debtor or alleged debtor.

 

11.         TERMINATION

 

11.1         Termination
by REGENTS: If LICENSEE violates or fails to perform any term of this AGREEMENT, the REGENTS may give written notice of such
default (“NOTICE OF DEFAULT”) to LICENSEE. If LICENSEE fails to repair such default within sixty (60) days after
the date such notice takes effect, the REGENTS will have the right to immediately terminate this AGREEMENT and the licenses hereunder
by providing a written notice of termination (“NOTICE OF TERMINATION”) to LICENSEE.

 

11.2         Termination
by LICENSEE: LICENSEE has the right at any time to terminate this AGREEMENT by providing a NOTICE OF TERMINATION to REGENTS.
Moreover, LICENSEE is entitled to terminate its rights under PATENT RIGHTS on a country-by-country basis by giving notice in writing
to REGENTS. The termination of this AGREEMENT will be effective no earlier than ninety (90) days from the effective date of such
notice.

 

12.         DISPOSITION
OF PRODUCTS UPON TERMINATION

 

12.1         Termination:
Within a period of one hundred and twenty (120) days after the date of termination, LICENSEE can complete any partially made or
rendered LICENSED PRODUCT, and SELL all previously made or partially made LICENSED PRODUCT, provided however, that the SALE of
such LICENSED PRODUCT or LICENSED METHOD is subject to the terms of this AGREEMENT including, but not limited to, the payment of
EARNED ROYALTIES at the times provided herein and the rendering of ROYALTY REPORTS in connection therewith. LICENSEE cannot otherwise
make, SELL, offer for SALE, distribute or import LICENSED PRODUCT, or practice the LICENSED METHOD after the date of termination.

 

12.2         Expiration.
If applicable PATENT RIGHTS existed at the time of any making, SALE, offer for SALE, distribution or import of a LICENSED PRODUCT
or LICENSED METHOD, then EARNED ROYALTIES will be paid at the times provided herein and ROYALTY REPORTS will be rendered in connection
therewith, notwithstanding the absence of applicable PATENT RIGHTS with respect to such LICENSE PRODUCT or LICENSED METHOD at any
later time. Otherwise, no EARNED ROYALTIES will be paid on such product.

 

    	Page 16 of 28

    	 

    

 

13.         PATENT
MARKING

 

13.1         US:
LICENSEE agrees to mark LICENSED PRODUCT (or their containers or labels) made, SOLD, licensed or otherwise disposed of by LICENSEE
in the U.S. under the license granted in this AGREEMENT (a) with the words “Patent Pending” prior to the issuance of
patents under PATENT RIGHTS, and (b) with the patent numbers of the PATENT RIGHTS following the issuance in the U.S. of one or
more patents under PATENT RIGHTS.

 

13.2         International:
All LICENSED PRODUCT shipped to, manufactured, or SOLD in countries outside of the U.S. will be marked in such manner as to conform
to the patent laws and practice of such countries.

 

14.         PATENT
PROSECUTION AND MAINTENANCE

 

14.1         Obligations:
REGENTS will diligently prosecute and maintain the U.S. and foreign patents and patent applications comprising the PATENT RIGHTS
using counsel of its choice who will take instructions solely from REGENTS, provided that the continued use of such counsel at
any point in the patent prosecution process subsequent to EFFECTIVE DATE is subject to the approval of LICENSEE. If LICENSEE rejects
five of REGENTS’ choices of prosecution counsel, then REGENTS can select new prosecution counsel without LICENSEE’s
consent.

 

14.2         Interaction:
REGENTS will promptly provide LICENSEE with copies of all relevant documentation including itemized billing statements from REGENTS’
counsel (“PATENT DOCUMENTATION”) so that LICENSEE will be informed and apprised of the continuing prosecution,
and LICENSEE agrees to keep PATENT DOCUMENTATION confidential in accordance with Confidentiality Article of this AGREEMENT. LICENSEE
and its patent counsel have the right to consult with the patent counsel chosen by REGENTS. REGENTS agree to designate one of the
named inventors of INVENTIONS as the inventors’ point of contact with REGENTS’ counsel subject to agreement with the
investors. The inventor’s point of contact will provide detailed input to REGENTS’ counsel subject to the approval
by REGENTS’ representative who will be copied or included in all communications.

 

14.3         Comments:
LICENSEE can comment on PATENT DOCUMENTATION sufficiently in advance of any initial deadline for filing a response, provided, however,
if LICENSEE has not commented upon PATENT DOCUMENTATION in reasonable time for REGENTS to sufficiently consider LICENSEE’s
comments prior to a deadline with the relevant government patent office, or if REGENTS will act to preserve PATENT RIGHTS, then
REGENTS is free to respond without consideration of LICENSEE’s comments, if any.

 

14.4         Claims
Requests: REGENTS will use reasonable efforts to amend any patent application to include claims requested by LICENSEE and required
to protect LICENSED PRODUCT contemplated to be SOLD, or LICENSED METHOD to be practiced, under this AGREEMENT.

 

    	Page 17 of 28

    	 

    

 

14.5         Foreign
Filing Requests: At LICENSEE’s request, and if available, REGENTS will file, prosecute, and maintain patent applications
and patents included under PATENT RIGHTS in foreign countries. REGENTS’ counsel will file Patent Cooperation Treaty applications
at the time of filing the U.S. non-provisional applications. LICENSEE will notify REGENTS within fifteen (15) months of the filing
of the correspondence U.S. patent application of its request for REGENTS to file foreign counterpart patent applications. This
notice concerning foreign filing will be in writing and will identify the countries desired. The absence of such a notice from
LICENSEE to REGENTS within the fifteen (15) month period will be considered an election by LICENSEE not to request REGENTS to secure
foreign PATENT RIGHTS on LICENSEE’s behalf. REGENTS has the right to file patent applications at its own expense in any country
that LICENSEE does not include in its list of desired countries, and such patent applications and resultant patents, if any, will
not be included in the licenses granted hereunder.

 

14.6         Costs:
LICENSEE will pay all costs of obtaining patentability opinions, preparing, filing, prosecuting in whatsoever manner, and maintaining
all U.S. and corresponding foreign patent applications and resulting patents specified under PATENT RIGHTS (“PATENT PROSECUTION
COSTS”), including, but not limited to, PATENT PROSECUTION COSTS incurred by REGENTS prior to the execution of this AGREEMENT
as well as interferences, oppositions, reexaminations, and reissues. LICENSEE will reimburse REGENTS for all PATENT PROSECUTION
COSTS within thirty (30) days following receipt of an itemized invoice from REGENTS for PATENT PROSECUTION COSTS except that
only up to five thousand dollars ($5,000) in invoices will be due prior to 2006 June 30, and any remaining amount will be due promptly
thereafter. However, if REGENTS reduces the exclusive licenses granted herein to non-exclusive licenses pursuant to the Due
Diligence Article of this AGREEMENT and REGENTS grants additional licenses, then the PATENT PROSECUTION COSTS will be divided equally
among the licensed parties from the effective date REGENTS give written notice to LICENSEE of the reduction of LICENSEE’s
exclusive license to a non-exclusive license.

 

14.7         Termination:
LICENSEE will pay any PATENT PROSECUTION COSTS incurred during the three (3)-month period after receipt by either party of a NOTICE
OF TERMINATION, even if the invoices for such PATENT PROSECUTION COSTS are received by REGENTS after the end of the three (3)-month
period following receipt of a NOTICE OF TERMINATION.

 

14.8         LICENSEE
may terminate its obligations to pay PATENT PROSECUTION COSTS with respect to any particular patent application or patent under
PATENT RIGHTS in any or all designated countries upon written notice to REGENTS. REGENTS may continue the prosecution and/or maintenance
of such patent application or patent at its sole discretion and expense, provided, however, that LICENSEE will have no further
rights or licenses thereunder.

 

    	Page 18 of 28

    	 

    

  

15.         PATENT
INFRINGEMENT

 

15.1         Obligations:
In the event that REGENTS (to the extent of the actual knowledge of the licensing professional responsible for the administration
of this AGREEMENT) or LICENSEE learns of infringement of potential commercial significance of any patent licensed under this AGREEMENT,
then the knowledgeable party will provide the other with written notice of such infringement and any evidence of such infringement
available to it (“INFRINGEMENT NOTICE”). During the period in which, and in the jurisdiction where, LICENSEE
has exclusive rights under this AGREEMENT, neither REGENTS nor LICENSEE will notify a third party (including the infringer) of
infringement or put such third party on notice of the existence of any PATENT RIGHTS without first obtaining consent of the other,
which shall not be unreasonably withheld. If LICENSEE notifies a third party of infringement or puts such third party on notice
of the existence of any PATENT RIGHTS with respect to such infringement without first obtaining the written consent of REGENTS,
then REGENTS will have the right to terminate this AGREEMENT immediately without the obligation to provide early notice as set
forth in this AGREEMENT. Both REGENTS and LICENSEE will use their diligent efforts to cooperate with each other to terminate such
infringement without litigation.

 

15.2         Licensee
Initiated Suit: If within ninety (90) days following the date that the INFRINGEMENT NOTICE takes effect, the infringing activity
of potential commercial significance by the infringer has not been abated, then LICENSEE may institute suit for patent infringement
against the infringer. REGENTS may voluntarily join such suit as its own expense, but may not thereafter commence suit against
the infringer for the acts of infringement that are the subject of LICENSEE’s suit or any judgment rendered in that suit.
LICENSEE may not join REGENTS in a suit initiated by LICENSEE without REGENTS’ prior written consent. In a suit initiated
by LICENSEE, if REGENTS is involuntarily jointed other than by LICENSEE, then LICENSEE will pay any costs incurred by REGENTS arising
out of such suit, including but not limited to, any legal fees of counsel that REGENTS selects and retains to represent REGENTS
in the suit.

 

15.3         REGENTS
Initiated Suit: If within a hundred and twenty (120) days following the date that the INFRINGEMENT NOTICE takes effect (a)
the infringing activity of potential commercial significance by the infringer has not been abated, and (b) LICENSEE has not brought
suit against the infringer, then REGENTS may institute suit for patent infringement against the infringer. If REGENTS institutes
such suit, then LICENSEE may not join such suit without REGENTS’ consent and may not thereafter commence suit against the
infringer for the acts of infringement that are the subject of REGENTS’ suit or any judgment rendered in that suit. In a
suit initiated by REGENTS, if LICENSEE is involuntarily joined other than by REGENTS, then REGENTS will pay any costs incurred
by LICENSEE arising out of such suit with respect to patent infringement, patent validity, and patent enforceability, including
but not limited to, any legal fees of counsel that REGENTS selects and retains to represent LICENSEE in the suit.

 

15.4         Allocation
of Recovery: Any recovery or settlement received in connection with any suit will first be shared by REGENTS and LICENSEE equally
to cover the litigation costs each incurred, and next will be paid to REGENTS or LICENSEE to cover any litigation costs that either
party incurred in excess of the litigation costs of the other. Any recovery in excess of litigation costs will be shared between
LICENSEE and REGENTS as follows:

 

15.4a   In any suit initiated
by REGENTS, any recovery in excess of litigation costs will belong to REGENTS;

 

15.4b   In any suit initiated
by LICENSEE, any recovery in excess of litigation costs will be shared between LICENSEE and REGENTS as follows:

 

    	Page 19 of 28

    	 

    

 

i.          If
REGENTS joins the suit, any recovery in excess of litigation costs will be shared in proportion to the costs incurred by each party,
but in no event will REGENTS proportion be less than ten percent (10%);

 

ii.         If
REGENTS do not join the suit, any recovery in excess of litigation costs will belong to LICENSEE.

 

15.5        Binding:
REGENTS and LICENSEE agree to be bound by all determinations of patent infringement, validity, and enforceability (but no other
issue) resolved by any adjudicated judgment in a suit brought in compliance with this Article.

 

15.6        Compliance:
Any agreement made by the LICENSEE for purposes of settling litigation or other dispute will comply with the requirements of the
Sublicense Article of this AGREEMENT.

 

15.7        Cooperation:
Each party will cooperate with the other in litigation proceedings instituted hereunder but at the expense of the party who initiated
the suit (unless such suit is being jointly prosecuted by the parties).

 

15.8        Control:
The party bringing the suit will control any litigation proceedings, except that REGENTS may be represented by counsel of its choice
in any suit brought by LICENSEE.

 

16.         LIMITED
WARRANTY

 

16.1        REGENTS
warrants to LICENSEE that REGENTS has the lawful right to grant this license.

 

16.2        Except
as expressly set forth in this AGREEMENT, the licenses and the associated INVENTION, PATENT RIGHTS, LICENSED PRODUCTS, and LICENSED
METHODS are provided by REGENTS WITHOUT WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR ANY OTHER WARRANTY OF
ANY KIND, EITHER EXPRESS OR IMPLIED. REGENTS MAKES NO EXPRESS OR IMPLIED REPRESENTATION OR WARRANTY THAT THE INVENTION, PATENT
RIGHTS, LICENSED PRODUCTS, OR LICENSED METHODS WILL NOT INFRINGE ANY PATENT, COPYRIGHT, TRADEMARK OR OTHER RIGHTS.

 

16.3        Nothing
in this AGREEMENT is or will be construed as:

 

16.3a   A warranty or representation
by REGENTS as to the validity, enforceability, or scope of any PATENT RIGHTS; or

 

16.3b   A warranty or representation
that anything made, used, SOLD, or otherwise exploited under any license granted in this AGREEMENT is or will be free from infringement
of patents, copyrights, or other rights of third parties; or

 

    	Page 20 of 28

    	 

    

 

16.3c   An obligation to bring
or prosecute actions or suits against third parties for patent infringement except as provided in the Patent Infringement Article
of this AGREEMENT; or

 

16.3d   Conferring by implication,
estoppel, or otherwise any license or rights under any patents or other rights of REGENTS other than PATENT RIGHTS, regardless
of whether such patents are dominant or subordinate to PATENT RIGHTS; or

 

16.3e   An obligation to furnish
any NEW DEVELOPMENTS, know-how, technology, or technological information not provided in PATENT RIGHTS.

 

17.         LIMITATION
OF LIABILITY

 

17.1        REGENTS
WILL NOT BE LIABLE FOR ANY LOST PROFITS, COSTS OF PROCURING SUBSTITUTE GOODS OR SERVICES, LOST BUSINESS, ENHANCED DAMAGES FOR INTELLECTUAL
PROPERTY INFRINGEMENT, OR FOR ANY INDIRECT, INCIDENTAL, CONSEQUENTIAL, PUNITIVE, OR OTHER SPECIAL DAMAGES SUFFERED BY LICENSEE,
SUBLICENSEES, JOINT VENTURES, OR AFFILIATES ARISING OUT OF OR RELATED TO THIS AGREEMENT FOR ALL CAUSES OF ACTION OF ANY KIND (INCLUDING
TORT, CONTRACT, NEGLIGENCE, STRICT LIABILITY AND BREACH OF WARRANTY) EVEN IF REGENTS HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH
DAMAGES.

 

18.         INDEMNIFICATION

 

18.1        Requirements:
LICENSEE will, and will require its SUBLICENSEES to, indemnify, hold harmless, and defend REGENTS and its officers, employees,
and agents, the sponsors of the research that led to the INVENTION, the inventors of any invention claimed in patents or patent
applications under PATENT RIGHTS (including the LICENSED PRODUCT, and LICENSED METHODS contemplated thereunder) and inventors’
employers against any and all claims, suits, losses, damage, costs, fees, and expenses resulting from, or arising out of, the exercise
of this license or any sublicense. This indemnification will include, but will not be limited to, any product liability. If REGENTS,
in its sole discretion, believes that there will be a conflict of interest or REGENTS will not otherwise be adequately represented
by counsel chosen by LICENSEE to defend REGENTS in accordance with this Paragraph, then REGENTS may retain counsel of its choice
to represent it, and LICENSEE will pay all expenses for such representation.

 

18.2        Insurance:
During the term of this AGREEMENT and for three (3) years following its termination or expiration, LICENSEE, at its sole cost and
expense, will insure its activities in connection with any work performed hereunder and will obtain and maintain insurance as follows:

 

    	Page 21 of 28

    	 

    

 

18.2a   Commercial Form General
Liability Insurance (contractual liability included) with limits as follows:

 

	i	 	Each Occurrence	 	$	1,000,000	 
	 	 	 	 	 	 	 
	ii	 	Products/Completed Operations Aggregate	 	$	1,000,000	 
	 	 	 	 	 	 	 
	iii	 	Personal and Advertising Injury	 	$	1,000,000	 
	 	 	 	 	 	 	 
	iv	 	General Aggregate	 	$	1,000,000	 

 

18.2b   The coverage and limits
referred to in the Subparagraph above will not in any way limit the liability of LICENSEE;

 

18.2c   LICENSEE will furnish
REGENTS with certificates of insurance evidencing compliance with all requirements. Such certificates will:

 

i.           Provide
for thirty (30) days’ advance written notice to REGENTS of any modification;

 

ii.          Indicate
that REGENTS has been endorsed as an additional insured under the coverage described above; and

 

iii.         Include
a provision that the coverage will be primary and will not participate with, nor will be excess over, any valid and collectable
insurance or program of self-insurance maintained by REGENTS.

 

18.3        Notification:
REGENTS will promptly notify LICENSEE in writing of any claim or suit brought against REGENTS for which REGENTS intends to invoke
the provisions of this Indemnification Article. LICENSEE will keep REGENTS informed of its defense of any claims pursuant to this
Indemnification Article.

 

19.         CONFIDENTIALITY

 

19.1        Obligation:
LICENSEE and REGENTS will treat and maintain the other party’s proprietary business, patent prosecution, software, engineering
drawings, process and technical information, and other proprietary information, including the negotiated terms of this AGREEMENT,
PROGRESS REPORTS, ROYALTY REPORTS and PATENT DOCUMENTATION (“CONFIDENTIAL INFORMATION”) in confidence using
at least the same degree of care as the receiving party uses to protect its own proprietary information of a like nature.

 

19.2        Disclosure:
LICENSEE and REGENTS may use and disclose CONFIDENTIAL INFORMATION to their employees, agents, consultants, contractors, and, in
the case of LICENSEE, its SUBLICENSEES, provided that such parties are bound by a like duty of confidentiality as that found in
this Confidentiality Article. Notwithstanding anything to the contrary contained in this AGREEMENT, REGENTS may release this AGREEMENT,
including any terms contained herein, and information regarding royalty payments or other income received in connection with this
AGREEMENT to the inventors, senior administrative officials employed by REGENTS, and individual Regents upon their request. If
such release is made, REGENTS will request that such terms be kept in confidence in accordance with the provisions of this Confidentiality
Article.

 

    	Page 22 of 28

    	 

    

 

19.3        Marking:
All written CONFIDENTIAL INFORMATION will be labeled or marked confidential or proprietary. If the CONFIDENTIAL INFORMATION is
orally disclosed, it will be reduced to writing or some other physically tangible form, marked and labeled as confidential or proprietary
by the disclosing party and delivered to the receiving party within thirty (30) days after the oral disclosure.

 

19.4        General
Exceptions: Nothing contained herein will in any way restrict or impair the right of LICENSEE or REGENTS to use or disclose
any CONFIDENTIAL INFORMATION:

 

19.4a   That recipient can demonstrate
by written records was previously known to it prior to its disclosure by the disclosing party;

 

19.4b   That recipient can demonstrate
by written records is now, or becomes in the future, public knowledge other than through acts or omissions of recipient;

 

19.4c   That recipient can demonstrate
by written records was lawfully obtained without restrictions on the recipient from sources independent of the disclosing party;
or

 

19.4d   That is required to be
disclosed pursuant to the California Public Records Act or other applicable law.

 

19.5        Other
Exceptions: LICENSEE or REGENTS may use or disclose CONFIDENTIAL INFORMATION that is required to be disclosed:

 

19.5a   To a governmental entity
or agency in connection with seeking any governmental or regulatory approval, governmental audit, or other governmental requirement;
or

 

19.5b   By law, provided that
the recipient uses reasonable efforts to give the party owning the CONFIDENTIAL INFORMATION sufficient notice of such required
disclosure to allow the party owning the CONFIDENTIAL INFORMATION reasonable opportunity to object to, and to take legal action
to prevent, such disclosure.

 

19.6        Inquiry
Exceptions: REGENTS also may disclose the existence of this AGREEMENT and the extent of the grant of license and sublicenses
herein to a third party that inquires whether a license to the PATENT RIGHTS is available, but REGENTS will not disclose the name
of LICENSEE, unless LICENSEE has already made such disclosure publicly.

 

19.7        Metric
Exceptions: REGENTS can publicly identify LICENSEE’s corporate name and contact information as an entity with which REGENTS
has an agreement that involves the commercialization of technology developed at the University of California, Berkeley; however
this exception does not cover other information about this AGREEMENT including INVENTIONS and INVENTORS when used in association
with LICENSEE’s name.

 

    	Page 23 of 28

    	 

    

 

19.8        Termination:
Upon termination of this AGREEMENT, LICENSE and REGENTS will destroy or return any of the disclosing party’s CONFIDENTIAL
INFORMATION in its possession within fifteen (15) days following the termination of this AGREEMENT. LICENSEE and REGENTS will provide
each other, within thirty (30) days following termination, with written notice that such CONFIDENTIAL INFORMATION has been returned
or destroyed. Each party may, however, retain one copy of such CONFIDENTIAL INFORMATION for archival purposes in non-working files.

 

19.9        Expiration:
The terms of this Confidentiality Article will expire in five (5) years from the effective date of termination of this AGREEMENT.

 

20.         NOTICES

 

20.1        Addresses:
Any notice or payment that is required to be given to either party will be deemed to have been properly given when done in writing
and deposited in the U.S. mail, registered or certified, addressed as follows or to another address as designated in writing by
the party changing its address:

 

20.1a   To LICENSEE:

 

		·	Berkeley ExoTech, Inc.

		·	63 Potomac Street

		·	San Francisco, CA 94117

		·	Telephone: 415-533-8062

		·	Facsimile: 775-366-1783

		·	Email: info@berkeleyexoworks.com

		·	Attention: President

 

20.1b   To REGENTS:

 

		·	Office of Technology Licensing

		·	2150 Shattuck Avenue, Suite 510

		·	Berkeley, CA 94720-1620

		·	Attn: Director (REGENTS Case Number BO4-002, BO5-045, BO5-093)

 

20.2        Effective
Date: Any such properly given notice or payment will be deemed to be effective as follows:

 

20.2a   On the date of delivery if
delivered in person;

 

20.2b   On the date of mailing if
mailed by first-class certified mail; or

 

20.2c   On the date of mailing
if mailed by any global express carrier service that requires the signature of recipient to demonstrate the delivery of such notice
or payment.

 

    	Page 24 of 28

    	 

    

  

21.         PAYMENTS

 

21.1         Payment
Method: All consideration due REGENTS will be payable in U.S. dollars. LICENSEE will make all payments to REGENTS under this
AGREEMENT by check payable to “The Regents of the University of California” and forward it to REGENTS in accordance
with the Notices Article 20.

 

21.2         Late
Payments: If any monies owed to REGENTS are not received by REGENTS when due, then LICENSEE will pay to REGENTS interest at
a rate of ten percent (10%) simple interest per annum. Interest will be calculated from the date payment was due until actually
received by REGENTS. Accrual of interest will be in addition to, and not in lieu of, enforcement of any other rights of REGENTS
due to late payment. Acceptance by REGENTS of any late payment from LICENSEE under this Article will in no way affect the provision
of the Waiver Article of this AGREEMENT.

 

21.3         Foreign
Money Restrictions: Notwithstanding the provisions of the Force Majeure Article of this AGREEMENT, if at any time legal restrictions
prevent prompt remittance of any monies or other consideration owed to REGENTS by the LICENSEE with respect to any country where
a sublicense is issued or a LICENSED PRODUCT or LICENSED METHOD is SOLD, then LICENSEE will convert the amount owed to REGENTS
into U.S. dollars and will pay REGENTS directly from another source of funds in order to remit the entire amount owed to REGENTS.

 

22.         GOVERNING
LAWS; VENUE; ATTORNEYS’ FEES

 

22.1         THIS
AGREEMENT WILL BE INTERPRETED AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF CALIFORNIA, excluding any choice of law
rules that would direct the application of the laws of another jurisdiction, but the scope and validity of any patent or patent
application will be governed by the applicable laws of the county of such patent or patent application.

 

22.2         Any
legal action related to this AGREEMENT will be conducted in San Francisco, California.

 

22.3         The
prevailing party in any suit related to this AGREEMENT will be entitled to recover its reasonable attorneys’ fees in addition
to its costs and necessary disbursements.

 

23.         GOVERNMENT
APPROVAL OR REGISTRATION

 

23.1         Obligation:
If the law of any nation requires that this AGREEMENT or any associated transaction be either approved or registered with any government
agency, then LICENSEE will assume all legal obligations to do so. LICENSEE will notify REGENTS if it becomes aware that this AGREEMENT
is subject to a U.S. or foreign government reporting or approval requirement.

 

23.2         Costs:
LICENSEE will make all necessary filings and pay all costs including fees, penalties, and other out-of-pocket costs associated
with such reporting or approval process.

 

    	Page 25 of 28

    	 

    

  

24.         GOVERNMENT
EXPORT AND IMPORT LAWS

 

24.1        LICENSEE
will comply with all applicable international, national, state, regional, and local laws and regulations in performing its obligations
hereunder and in its use, manufacture, SALE, or import of the LICENSED PRODUCT or practice of the LICENSED METHOD.

 

24.2        LICENSEE
will observe all applicable U.S. and foreign laws with respect to the transfer or provision of LICENSED PRODUCT and related technical
data to foreign countries, including, without limitation, the International Traffic in Arms Regulations (ITAR) and the Export Administration
Regulations.

 

24.3        When
LICENSED PRODUCT is made outside the particular country in which such LICENSED PRODUCT is used, SOLD, or otherwise exploited, then
LICENSEE will manufacture LICENSED PRODUCT or practice LICENSED METHOD in compliance with applicable government importation laws
and regulations of the particular country.

 

25.         MISCELLANEOUS

 

25.1        Use
of Names and Trademarks: Nothing contained in this AGREEMENT will be construed as conferring any right to either party to use
in advertising, publicity, or other promotional activities any name, trade name, trademark, or other designation of the other party
(including a contraction, abbreviation or simulation of any of the foregoing). LICENSEE is expressly prohibited from using the
name “The Regents of the University of California” or the name of any campus of the University of California in advertising,
publicity, or other promotional activities, unless written consent is obtained by LICENSEE from REGENTS to do so. LICENSEE may
provide a copy of this AGREEMENT to investors and potential investors. Notwithstanding the foregoing, without the consent of REGENTS,
LICENSEE and its AFFILIATES and SUBLICENSEES may state that it or they are licensed by REGENTS under one or more of the patents
and/or patent applications comprising the PATENT RIGHTS, and that the REGENTS are an equity holder in LICENSEE.

 

25.2        Assignment:

 

25.2a   LICENSEE: This
AGREEMENT is personal to LICENSEE and assignable by LICENSEE only with the written consent of REGENTS, except that LICENSEE may
freely assign this AGREEMENT to an acquirer of all or substantially all of LICENSEE’s stock, assets or business;

 

25.2b   REGENTS: This
AGREEMENT is binding upon and will inure to be the benefit of REGENTS, its successors and assigns.

 

25.3        Waiver:

 

25.3a   No waiver by either party
of any breach or default of any of the duties, obligations, or agreements contained herein will be deemed a waiver as to any subsequent
and/or similar breach or default;

 

25.3b   No waiver will be valid
or binding upon the parties unless made in writing and signed by a duly authorized officer of each party.

 

    	Page 26 of 28

    	 

    

 

25.4        Force
Majeure

 

25.4a   Responsibility:
Except for LICENSEE’s obligation to make any payments to REGENTS hereunder, the parties will not be responsible for any failure
to perform due to the occurrence of any events beyond their reasonable control which render their performance impossible or onerous,
including, but not limited to: accidents (environmental, toxic spill, etc.); acts of God; biological or nuclear incidents; casualties;
earthquakes; fires; floods; governmental acts, orders or restrictions; inability to obtain suitable and sufficient labor, transportation,
fuel and materials; local, national, or state emergency; power failure and power outages; acts of terrorism; strike, and war;

 

25.4b   Termination: Either
party to this AGREEMENT, however, will have the right to terminate this AGREEMENT upon thirty (30) days’ prior written notice
if either party is unable to fulfill its obligations under this AGREEMENT due to any of the causes specified in the Paragraph above
for a period of one (1) year.

 

25.5        Severability:
If any of the provisions contained in this AGREEMENT are held to be invalid, illegal, or unenforceable in any respect, such invalidity,
illegality, or unenforceability will not affect any other provisions hereof, and this AGREEMENT will be construed as if such invalid
or illegal or unenforceable provisions had never been contained herein.

 

25.6        Scope:
This AGREEMENT embodies the entire understanding of the parties and supersedes all previous communications, representations, or
understandings, whether oral or written, between the parties relating to the subject matter hereof. The PREVIOUS AGREEMENT specified
in the Background Section of this AGREEMENT is hereby terminated.

 

25.7        Amendments:
No amendment or modification of this AGREEMENT will be valid or binding upon the parties unless made in writing and signed on behalf
of each party.

 

25.8        Parties:
No provisions of this Agreement are intended or will be construed to confer upon or given to any person or entity other than REGENTS
and LICENSEE any rights, remedies, or other benefits under, or by reason of, this AGREEMENT.

 

25.9        Independence:
In performing their respective duties under this AGREEMENT, each of the parties will be operating as an independent contractor.
Nothing contained herein will in any way constitute any association, partnership, or joint venture between the parties hereto,
or be construed to evidence the intention of the parties to establish any such relationship. Neither party will have the power
to bind the other party or incur obligations on the other party’s behalf without the other party’s prior written consent.

 

25.10        Headings:
The headings of the sections are inserted for convenience of reference only and are not intended to affect the meaning or interpretation
of this AGREEMENT.

 

    	Page 27 of 28

    	 

    

 

In witness whereof, both REGENTS and LICENSEE
have executed this AGREEMENT, in duplicate originals, by their respective officers hereunto duly authorized, on the date and year
hereinafter written.

 

	Berkeley ExoWorks	 	The Regents of the University of
    California
	 	 	 	 	 
	By 	/s/ Nathan Harding  	 	By	/s/ Veronica Lanier
	(Signature)	 	(Signature)  
	 	 	 	 	 
	Name 	Nathan Harding  	 	Name	Veronica Lanier
	(Please Print)	 	(Please Print)
	 	 	 	 	 
	Title 	Chief Financial Officer  	 	Title	Acting Director, Office of Technology Licensing
	 	 	 	 	 
	Date 	November 2, 2005  	 	Date	November 15, 2005

 

    	Page 28 of 28Exhibit 10.20

 

EXCLUSIVE LICENSE AGREEMENT
FOR:

MECHANISM TO ENABLE NORMAL GAIT DESPITE LEG INJURIES,

DECREASING OXYGEN CONSUMPTION BY USE OF A

LOAD-CARRYING EXOSKELETON,

UNDER-ACTUATED TRANSFEMORAL PROSTHETIC KNEE, AND

CONTROLLING THE SWINGING LEG OF AN EXOSKELETON

UC Case Numbers: B07-128, B08-119, B08-125, B08-141

 

This license agreement (“AGREEMENT”)
is entered into as of the date that this AGREEMENT is fully executed by both parties (“EFFECTIVE DATE”), by
and between The Regents of the University of California, a California corporation, having its statewide administrative offices
at 1111 Franklin Street, 12th Floor, Oakland, California 94607-5200 acting through its Office of Technology Licensing,
at the University of California, Berkeley, having its administrative office at 2150 Shattuck Avenue, Suite 510, Berkeley, CA 94720-1620
(“REGENTS”), and Berkeley ExoTech, Inc. dba Berkeley Bionics and formerly dba Berkeley ExoWorks (“LICENSEE”),
a Delaware corporation, having a principal place of business at 2131 University Avenue, #428, Berkeley, CA
94704. The parties agree as follows:

 

1.           BACKGROUND

 

1.1          REGENTS
has an assignment of the intellectual property characterized as (collectively “INVENTIONS”):

 

1.1a     Mechanism to Support Those
with Lower Leg Injuries While Enabling Them to Walk with a Near Normal Gait as described in REGENTS Case Number B07-128 and PATENT
RIGHTS that was invented by Homayoon Kazerooni, Sara Marie Haislip, Jonathan Ames, and Esha Datta, all employed by the University
of California, Berkeley at the time that the invention was made;

 

1.1b     Device and Method for
Decreasing Oxygen Consumption of a Person During Steady Walking by Use of a Load-Carrying Exoskeleton as described in REGENTS Case
Number B08-119 and PATENT RIGHTS that was invented by Homayoon Kazerooni and Kurt Amundson, all employed by the University of California,
Berkeley at the time that the invention was made, and also invented by Russ Angold and Nathan Harding, all employed by LICENSEE
at the time that the invention was made; accordingly, the patent rights for this invention are expected to be jointly-owned between
REGENTS and LICENSEE;

 

1.1c     Under-Actuated Transfemoral
Prosthetic Knee as described in REGENTS Case Number B08-125 and PATENT RIGHTS that was invented by Homayoon Kazerooni, Bram Gilbert,
Antoon Lambrecht, Sebastian Kruse, and Matthew Rosa, all employed by the University of California, Berkeley at the time that the
invention was made, and also invented by Dylan Miller Fairbanks, Adam Zoss, and Minerva Pillai, all employed by LICENSEE at the
time that the invention was made; accordingly, the patent rights for this invention are expected to be jointly-owned between REGENTS
and LICENSEE; and

 

    	Page 1 of 34

    	 

    

  

1.1d     A Method for Controlling
the Swing Leg of an Exoskeleton as described in REGENTS Case Number B08-141 and PATENT RIGHTS that was invented by Homayoon Kazerooni,
employed by the University of California, Berkeley at the time that the invention was made, and also invented by Kurt Amundson
and Russ Angold, all employed by LICENSEE at the time the invention was made; accordingly, the patent rights for this invention
are expected to be jointly-owned between REGENTS and LICENSEE.

 

1.2          LICENSEE
and REGENTS jointly own the intellectual property resulting from the INVENTIONS described in Paragraphs 1.1b, 1.1c and 1.1d.

 

1.3          LICENSEE
has another exclusive license agreement (“OTHER RELATED LICENSE AGREEMENT”) with REGENTS that is related to
REGENTS Case Numbers B04-002, B05-045, B05-093, and B06-042. The OTHER RELATED LICENSE AGREEMENT will co-exist with this AGREEMENT;
moreover the technology, applications and markets associated with the OTHER RELATED LICENSE AGREEMENT are related to the technology,
applications and markets associated with this AGREEMENT.

 

1.4          LICENSEE
provided REGENTS with a marketing overview and financial forecasts for the commercialization of the INVENTIONS in order to evaluate
LICENSEE’s capabilities as a LICENSEE.

 

1.5          In
accordance with Paragraph 3.3 of this AGREEMENT, the development of the INVENTIONS in Paragraphs 1.1b (B08-119) and 1.1c
(B08-025) were sponsored in part by various grants from U.S. Government agencies, and as a consequence, REGENTS elected to
retain title to the INVENTIONS subject to the rights and regulations of the U.S. Government under 35 USC 200-212 and implementing
regulations, including REGENTS’s grant to the U.S. Government of a non-exclusive, non-transferable, irrevocable, paid-up
license to practice or have practiced the INVENTIONS for or on behalf of the U.S. Government throughout the world. These U.S. Government
grants are DARPA Contract No. DAD19-01-1-0509.

 

1.6          LICENSEE
requested certain rights from REGENTS to commercialize the INVENTIONS.

 

1.7          REGENTS
wishes to respond to the request of the LICENSEE by granting the following rights to the LICENSEE to enable the general public
to enjoy the products and other benefits derived from the INVENTION.

 

2.           DEFINITIONS

 

As used in this AGREEMENT, the following
terms, whether used in the singular or plural, have the following meanings:

 

    	Page 2 of 34

    	 

    

 

2.1          “PATENT
RIGHTS” excludes any rights in and to NEW DEVELOPMENTS, and means the PATENT CLAIMS of, to the extent assigned
to or otherwise obtained by REGENTS, (a) the U.S. patents and patent applications, (b) the corresponding foreign patents and patent
applications, and (c) any reissues, extensions, substitutions, continuations, divisions, and continuation-in-part applications
(but only those PATENT CLAIMS in the continuation-in-part applications that are entirely supported in the specification and entitled
to the priority date of the parent application) that are based on future patents and patent application for the following:

 

2.1a     The INVENTION described
in Paragraph 1.1a, Mechanism to Support Those With Lower Leg Injuries While Enabling Them to Walk With a Near Normal Gait, filed
by Homayoon Kazerooni, Sara Marie Haislip, Esha Datta, and Jonathan Ames;

 

2.1b     The INVENTION described
in Paragraph 1.1b, Device and Method for Decreasing Oxygen Consumption of a Person During Steady Walking by Use of a Load-Carrying
Exoskeleton, filed by Homayoon Kazerooni, Kurt Amundson, Nathan Harding, Russ Angold;

 

2.1c     The INVENTION described
in Paragraph 1.1c, Under-Actuated Transfemoral Prosthetic Knee, filed by Homayoon Kazerooni, Bram Gilbert Antoon Lambrecht, Sebastian
Kruse, Matthew Rosa, Dylan Miller Fairbanks, Adam Zoss, and Minerva Pillai; and

 

2.1d     The INVENTION described
in Paragraph 1.1d, A Method for Controlling the Swing Leg of an Exoskeleton, filed by Homayoon Kazerooni, Kurt Amundson and Russ
Angold.

 

2.2          “PATENT
CLAIM” means a claim of a patent or patent application in any country that (a) has not expired; (b) has not been disclaimed;
(c) has not been cancelled or superseded, or if cancelled or superseded, has been reinstated; and (d) has not been revoked, held
invalid, or otherwise declared unenforceable or not allowable by a tribunal or patent authority of competent jurisdiction over
such claim in such country from which no further appeal has or may be taken.

 

2.3          “NEW
DEVELOPMENT” means inventions, or claims to inventions, which constitute advancements, developments, or improvements,
whether or not patentable and whether or not the subject of any patent application, but if patentable, are not sufficiently supported
by the specification of a previously-filed patent or patent application within the PATENT RIGHTS to be entitled to the priority
date of the previously-filed patent or patent application.

 

2.4          “LICENSED
PRODUCT” means any product, service, kit, material, or apparatus either (a) produced by, used in, or required for the
practice of LICENSED METHOD, or (b) the manufacture, use, SALE, offer for SALE, distribution, or import of which, which for both
(a) and (b) in the absence of the license granted in this AGREEMENT, would infringe, or contribute to, or induce the infringement
of, any PATENT RIGHTS were they issued in a country at the time of the infringing activity in that country. The definition of LICENSED
PRODUCT includes LICENSED METHOD (as defined below).

 

    	Page 3 of 34

    	 

    

 

2.5          “LICENSED
METHOD” means any process, service or method the use or practice of which, in the absence of the license granted in this
AGREEMENT, would infringe, or contribute to, or induce the infringement of any PATENT RIGHTS were they issued in a country at the
time of the infringing activity in that country.

 

2.6          “LICENSED
FIELD-OF-USE” means the following applications or markets: all applications and markets without limitation (no
restrictions).

 

2.7          LICENSED
TERRITORY” means jurisdictions where REGENTS has obtained, or obtains PATENT RIGHTS, or filed corresponding patent applications
under PATENT RIGHTS.

 

2.8          “SUBLICENSEE”
means the third parties, AFFILIATES or JOINT VENTURES that, to the extent allowable by this AGREEMENT, are granted a sublicense
by LICENSEE to practice LICENSED METHOD, or to make, have made, use, SELL, offer for SALE, distribute or import LICENSED PRODUCT.
For purposes of clarity, the term SUBLICENSEE excludes end-users of a LICENSED PRODUCT, or other similar instances where “use”
is the only PATENT RIGHT granted to such third party.

 

2.9          “SALE”
means the act of selling, leasing or otherwise transferring, providing, exploiting or furnishing for use for any consideration.
Correspondingly, “SELL” means to make a SALE or cause a SALE to be made, and “SOLD” means to have made
a SALE or caused a SALE to have been made.

 

2.10        “COMBINATION
LICENSED PRODUCT” means a LICENSED PRODUCT that is a combination of one or more LICENSED PRODUCTS with one or more products
that are not LICENSED PRODUCTS (“NLPs”) where such NLP(s) has independent value from the LICENSED PRODUCT (i.e., the
COMBINATION PRODUCT incorporating or using such NLP has a higher value or utility than the applicable LICENSED PRODUCT without
such NLP).

 

2.11        “NET
INVOICE PRICE” means the gross invoice price charged and the value of any other consideration received for a SALE of
a LICENSED PRODUCT or the performance of a LICENSED METHOD when SOLD or performed by LICENSEE or SUBLICENSEE, less the following
items, but only to the extent that they actually pertain to the disposition of LICENSED PRODUCT, LICENSED METHOD, COMBINATION LICENSED
PRODUCT (as defined below), or combination thereof, and are separately billed:

 

i.          Allowances
actually granted to customers for rejections, returns, prompt payment or volume discounts;

 

ii.         Freight,
transport packing, or insurance charges associated with transportation;

 

iii.        Taxes,
including DEDUCTIBLE VALUE-ADDED TAX, tariffs or import/export duties based on SALES when included in the gross invoice price,
but excluding value-added taxes other than DEDUCTIBLE VALUE-ADDED TAX or taxes assessed on income derived from SALES. “DEDUCTIBLE
VALUE-ADDED TAX” means value-added tax only to the extent that such value-added tax is actually incurred and is not reimbursable,
refundable, or creditable under the tax authority of any country;

 

    	Page 4 of 34

    	 

    

  

iv.        Discounts
or rebates paid or credited to customers, third-party payers, health-care systems, or administrators solely to promote the inclusion
of LICENSED PRODUCT in formulary programs;

 

v.         Wholesaler’s
discounts or rebates to customers, third-party payers, health-care systems, or administrators solely to promote the inclusion of
LICENSED PRODUCT in formulary programs; and

 

vi.        Rebates
or discounts paid or credited pursuant to applicable law.

 

2.12       “NET
SALES PRICE” means the NET INVOICE PRICE except in the instances described as follows:

 

2.12a     In those instances where
LICENSED PRODUCT, or LICENSED METHOD is not SOLD, but is otherwise exploited, the NET SALES PRICE for the purpose of computing
royalties for LICENSED PRODUCT and LICENSED METHOD are determined as follows:

 

i.           If
LICENSEE and/or any SUBLICENSEE are currently offering for SALE products or services that are the same or similar to LICENSED PRODUCT
or LICENSED METHOD, then the NET SALES PRICE for LICENSED PRODUCT or LICENSED METHOD otherwise exploited is the NET INVOICE PRICE
of products or services of the same or similar kind and quality, SOLD in similar quantities, currently being offered for SALE by
the LICENSEE and/or any SUBLICENSEE; or

 

ii.         If
LICENSEE and/or any SUBLICENSEE are not currently offering for SALE products or services that are the same or similar to
LICENSED PRODUCT or LICENSED METHOD, then NET SALES PRICE for a LICENSED PRODUCT or LICENSED METHOD otherwise exploited, is the
average NET INVOICE PRICE at which products or services of the same or similar kind and quality, SOLD in similar quantities, are
currently being offered for SALE by other manufacturers; or

 

iii.         If
LICENSEE, SUBLICENSEE and/or any other companies are not currently offering for SALE products or services that are the same
or similar to LICENSED PRODUCT or LICENSED METHOD, then the NET SALES PRICE for LICENSED PRODUCT or LICENSED METHOD otherwise exploited,
is the LICENSEE’s and/or any SUBLICENSEE’s costs of manufacture of LICENSED PRODUCT or costs of performing LICENSED
METHOD, determined by the customary accounting procedures of the LICENSEE and/or any SUBLICENSEE, plus one-hundred percent (100%)
of those costs.

 

2.12b     Sales of COMBINATION
LICENSED PRODUCTS: The applicable NET SALES PRICE for any COMBINATION LICENSED PRODUCT will be calculated by

 

    	Page 5 of 34

    	 

    

 

iMultiplying the NET INVOICE
PRICE of the COMBINATION LICENSED PRODUCT by the ratio of the average NET INVOICE PRICE of the LICENSED PRODUCT included in the
combination (during the six-month period in which such combination SALE occurred) to the sum of the average NET INVOICE PRICE of
each of the LICENSED PRODUCT and the NLPs included in the combination (during the six-month period in which such combination SALE
occurred); or

 

ii           If an item included in the
combination is not offered for SALE by LICENSEE, then

 

ii1.          The
NET INVOICE PRICE of the item will equal the average NET INVOICE PRICE at which products of the same or similar kind and quality,
sold in similar quantities, are offered for SALE by other manufacturers (during the six months in which such combination SALE occurred)
to the extent such information is readily available to LICENSEE; or

 

ii2.          If
the items are not offered for SALE by LICENSEE or any other company or cannot be reasonably ascertained by LICENSEE, then the NET
INVOICE PRICE of the item will equal LICENSEE’s cost of goods sold (“COGS”) related to the manufacture
of the item as determined by the customary accounting procedures of LICENSEE, plus one-hundred percent (100%) of those COGS.

 

2.12c     For a REACQUISITION SALE
OR EXPLOITATION, the NET SALES PRICE means the NET INVOICE PRICE upon final SALE of LICENSED PRODUCT by LICENSE or SUBLICENSEE.
“REACQUISITION SALE OR EXPLOITATION” means those instances where the LICENSEE acquires LICENSED PRODUCT or a
SUBLICENSEE acquires LICENSED PRODUCT, and then subsequently SELLS such LICENSED PRODUCT.

 

2.12d     For any reason RELATIONSHIP-INFLUENCED
SALE of LICENSED PRODUCT or LICENSED METHOD, the NET SALES will be based on the NET INVOICE PRICE at which the RELATIONSHIP-INFLUENCED
SALE PURCHASER resells LICENSED PRODUCT (and not in addition to the NET INVOICE PRICE charge by LICENSEE or SUBLICENSEE for such
LICENSED PRODUCT to the RELATIONSHIP-INFLUENCE SALE PURCHASER). “RELATIONSHIP-INFLUENCED SALE” means a SALE
of LICENSED PRODUCT or LICENSED METHOD, between LICENSEE and any SUBLICENSEE or between LICENSEE and/or SUBLICENSEE and an AFFILIATE,
a JOINT VENTURE, or a RELATED PARTY. “RELATIONSHIP-INFLUENCED SALE PURCHASER” means the purchaser of LICENSED
PRODUCT or LICENSED METHOD in a RELATIONSHIP-INFLUENCED SALE.

 

2.13       “AFFILIATE”
means any entity that, directly or indirectly, CONTROLS LICENSEE or SUBLICENSEE, is CONTROLLED by LICENSEE or SUBLICENSEE, or is
under common CONTROL with LICENSEE or SUBLICENSEE. “CONTROL” means as follows: (a) having the actual, present
capacity to elect a majority of the directors of such AFFILIATES; (b) having the power to direct at least forty percent (40%) of
the voting rights entitled to elect directors; or (c) in any country where the local law will not permit foreign equity participation
of a majority, then ownership or control, directly or indirectly, of the maximum percentage of such outstanding stock or voting
rights permitted by local law.

 

    	Page 6 of 34

    	 

    

  

2.14        “JOINT
VENTURE” means any separate entity established pursuant to an agreement between (a) a third party, and (b) LICENSEE and/or
SUBLICENSEE to institute a vehicle for a joint venture, in which the separate entity manufactures, uses, purchases, SELLS, or acquires
LICENSED PRODUCT from LICENSEE and/or SUBLICENSEE.

 

2.15        “RELATED
PARTY” means a corporation, firm, or other entity with which, or individual with whom, LICENSEE and/or SUBLICENSEE (or
any of their respective stockholders, subsidiaries or AFFILIATES) have an agreement, understanding, or arrangement (for example,
but not by way of limitation, an agreement providing LICENSEE and/or SUBLICENSEE with an option to purchase stock or other equity
interest, or a share of revenue or profits), that (a) is unrelated to the SALE of LICENSED PRODUCT and without which such other
agreement, understanding, or arrangement, the amounts, if any, charged by LICENSEE or SUBLICENSEE to such entity or individual
for LICENSED PRODUCT, would be higher than the NET INVOICE PRICE actually received, or (b) if such agreement, understanding, or
arrangement results in LICENSEE or SUBLICENSEE extending to such entity or individual lower prices for LICENSED PRODUCT than those
charged to others without such agreement, understanding, or arrangement buying similar products or services in similar quantities.

 

3.           GRANT
OF LICENSEGRANT OF LICENSE

 

3.1          Licensee
Grant: Subject to the limitations set forth in this AGREEMENT, including the license granted to the U.S. Government and rights
reserved for REGENTS as well as other educational and nonprofit institutions, REGENTS hereby grants to LICENSEE an exclusive license
under PATENT RIGHTS to make, have made, use, SELL, offer for SALE, distribute and import LICENSED PRODUCT and to practice LICENSED
METHOD in LICENSED FIELD-OF-USE in LICENSED TERRITORY.

 

3.2          Reserved
Rights: REGENTS expressly reserves the rights to (a) publish any and all technical data resulting from any research performed
by REGENTS relating to the INVENTION, (b) make and use the INVENTION and related technology for educational and research purposes,
(c) disseminate tangible materials associated with, or required to practice the INVENTION and/or PATENT RIGHTS to researchers at
nonprofit institutions for educational and research purposes, and (d) allow other educational and nonprofit institutions to make
and use the INVENTION and related technology for educational and research purposes.

 

3.3          Government
Obligations: For the PATENT RIGHTS associated with Paragraphs 2.1b (Case B08-119) and 2.1c (Case B08-125), The licenses granted
in this AGREEMENT are subject to the overriding obligations to the U.S Government including:

 

3.3a     In accordance with 35
USC §200-212 and implementing regulations, REGENTS has granted back to the U.S. Government a non-exclusive, non-transferable,
irrevocable, paid-up license to practice or have practiced INVENTIONS for or on behalf of the U.S. Government throughout the world.

 

    	Page 7 of 34

    	 

    

  

3.3b     In accordance with 37
CFR §401.14(h), REGENTS has an obligation to report on the utilization of the INVENTIONS; and in order to fulfill this obligation,
LICENSEE has a continuing responsibility to keep REGENTS informed of the large/small entity status (as defined in 15 USC §632)
of LICENSEE and its SUBLICENSEES.

 

3.3c     In accordance with PL
96-517 as amended by PL 98-620, to the extent required by law or regulation, LICENSED PRODUCT that is exclusively SOLD in the U.S.
will be substantially manufactured in the U.S.

 

4.          GRANTS
OF SUBLICENSES

 

4.1          Sublicense
Grant: REGENTS hereby grants to LICENSEE the right to issue sublicenses to SUBLICENSEES to make, have made, use, SELL, offer
for SALE, distribute or import LICENSED PRODUCT and to practice the LICENSED METHOD in LICENSED FIELD-OF-USE in LICENSED TERRITORY,
provided that LICENSEE has exclusive rights under this AGREEMENT on the effective date of the sublicense agreement. For the avoidance
of doubt, AFFILIATES and JOINT VENTURES do not have licenses under the PATENT RIGHTS unless such AFFILIATES and JOINT VENTURES
are granted a sublicense.

 

4.2          Terms:
To the extent applicable, all sublicenses will include all of the rights of, and will require the performance of all the obligations
due to REGENTS and, if applicable, to the U.S. Government, that are contained in this AGREEMENT, including, but not limited to,
at least the following terms:

 

4.2a     A statement setting forth
the date upon which LICENSEE’s exclusive rights, privileges, and license hereunder will expire;

 

4.2b     The same provision for
indemnification of REGENTS as has been provided for in this AGREEMENT; and

 

4.2c     A statement such that,
to the extent applicable, the obligations of this AGREEMENT will be binding upon the SUBLICENSEE as if it were in place of LICENSEE,
except as follows:

 

i.          EARNED
ROYALTY rates, MINIMUM ANNUAL ROYALTIES, and fees and other consideration due to LICENSEE may be higher than those specified
in this AGREEMENT; and

 

ii.         SUBLICENSEES
will be precluded from granting further sublicenses of PATENT RIGHTS unless agreed to in writing by REGENTS.

 

4.3          Notification:
LICENSEE will notify REGENTS of each sublicense granted pursuant to this AGREEMENT, and furnish to REGENTS a summary of the material
terms of each sublicense agreement.

 

    	Page 8 of 34

    	 

    

 

4.4          Responsibilities:
For the purposes of this AGREEMENT, the operations of all SUBLICENSEES are deemed to be the operations of LICENSEE, for which LICENSEE
is responsible. Also, LICENSEE will guarantee and deliver the payment of all monies due REGENTS from SUBLICENSEES; and LICENSEE
will collect and deliver all reports due REGENTS from SUBLICENSEES.

 

4.5          Termination:
Upon termination of this AGREEMENT for any reason, REGENTS, at its sole discretion, will determine whether any or all sublicenses
that are granted pursuant to this AGREEMENT will be canceled or remain in effect and assigned to REGENTS, but if REGENTS opts to
assign sublicenses to REGENTS, then REGENTS will not be bound to perform any duties or obligations set forth in any such sublicenses
that extend beyond the duties and obligations of REGENTS as set forth in this AGREEMENT.

 

4.6          Sublicense
Consideration: LICENSEE will pay to REGENTS twenty percent (20%) of any cash and of the cash equivalent of other
consideration owed to LICENSEE for the grant of rights under each sublicense agreement of PATENT RIGHTS in addition to all other
payments by LICENSEE to REGENTS as specified in this AGREEMENT including EARNED ROYALTIES. Such fees will be due to REGENTS on
the February 28 following the year in which the fee was accrued.

 

4.7          Comprehensive
Commercialization: If REGENTS (to the extent of the actual knowledge of the licensing professional responsible for administrating
this AGREEMENT) or a third party discovers that the INVENTIONS are useful for an application covered by the LICENSED FIELD-OF-USE,
but for which LICENSEE and its SUBLICENSEES have not developed or are not currently developing LICENSED PRODUCT or LICENSED METHOD
(“NEW APPLICATION”), then:

 

4.7a     REGENTS may give written
notice to LICENSEE identifying the NEW APPLICATION, except for the following: (a) information that is subject to restrictions of
confidentiality with third parties, or (b) information that originates with REGENTS personnel who do not assent to its disclosure
to LICENSEE. If REGENTS gives such written notice to LICENSEE, then LICENSEE will have ninety (90) days to give REGENTS written
notice stating whether LICENSEE elects to develop LICENSED PRODUCT or LICENSED METHOD for the application.

 

4.7b     If LICENSEE elects to
develop and commercialize LICENSED PRODUCT or LICENSED METHOD for the NEW APPLICATION, then LICENSEE will submit a commercialization
plan with performance milestones and PROGRESS REPORT to REGENTS in accordance with the Progress Report Article of this AGREEMENT.

 

4.7c     If LICENSEE elects not
to develop and commercialize LICENSED PRODUCT or LICENSED METHOD for the NEW APPLICATION, then REGENTS may seek third parties to
develop and commercialize LICENSED PRODUCT or LICENSED METHOD for the NEW APPLICATION. If REGENTS is successful in finding a third
party, it will refer such third party to LICENSEE. If the third party requests a sublicense under this AGREEMENT, then LICENSEE
will report the request to REGENTS within thirty (30) days from the date of such request.

 

    	Page 9 of 34

    	 

    

  

i.          If
such request results in a sublicense, then LICENSEE will report it to REGENTS in accordance with this AGREEMENT.

 

ii.         If
LICENSEE has not granted a sublicense to the third party within six (6) months after receiving such request, then within thirty
(30) days after such refusal, LICENSEE will submit to REGENTS a report specifying the license terms proposed by the third party
and a written justification for LICENSEE’s refusal to grant the proposed sublicense. If REGENTS, at its sole discretion,
determines that the terms of the sublicense proposed by the third party are reasonable under the totality of the circumstances,
taking into account LICENSEE’s LICENSED PRODUCTS or LICENSED METHOD in development, then REGENTS will have the right to grant
to the third party a license to make, have made, use, SELL, offer for SALE, distribute and import LICENSED PRODUCTS or LICENSED
METHOD for use in the LICENSED FIELD-OF-USE at substantially the same terms most recently proposed to LICENSEE by that the third
party and providing royalty rates that are at least equal to those paid by LICENSEE.

 

5.           FEES

 

5.1          Issue
Fee: As partial consideration for all rights and licenses granted by REGENTS to LICENSEE herein, LICENSEE will pay to REGENTS
a license issue fee of ten thousand dollars ($10,000) due and payable at the execution of this AGREEMENT.

 

5.2          Fee
Notes: The license issue fee is not refundable, not creditable, and not an advance against any other payments by LICENSEE to
REGENTS pursuant to this AGREEMENT.

 

6.           ROYALTIES

 

6.1          Applicability:
EARNED ROYALTIES will be payable on LICENSED PRODUCT and LICENSED METHOD covered by PATENT RIGHTS.

 

6.2          Rate:
As further consideration for all LICENSEE’s rights and licenses granted herein, LICENSEE will pay to REGENTS an earned royalty
based on the NET SALES PRICE (“EARNED ROYALTY”) at the rate of one percent (1%) based on the NET
SALES PRICE of LICENSED PRODUCT or LICENSED METHOD.

 

6.2a     No Double Royalty:
If Licensee pays to REGENTS an earned royalty based on NET SALES PRICE in the performance of OTHER RELATED LICENSE AGREEMENT, then
LICENSEE will not pay to REGENTS any EARNED ROYALTY on such NET SALES PRICE in the performance of this AGREEMENT,

 

6.3          Schedule:
EARNED ROYALTIES accruing to REGENTS will be paid to REGENTS semi-annually on or before the following dates of each calendar year:

 

		·	February 28 for the calendar six months ending December 31

 

    	Page 10 of 34

    	 

    

  

		·	August 31 for the calendar six months ending June 30

 

6.4          Minimum
Annual Royalty: LICENSEE will pay to REGENTS a minimum annual royalty in the amounts as set forth below, by February 28 of
the calendar year in which payment is due, and each payment will be credited against the EARNED ROYALTY due and owing for the calendar
year in which each payment is made.

 

		·	Beginning in the first calendar year after the first occurrence of NET SALES PRICE that is royalty bearing (in other words,
not SOLD or reSOLD to the U.S. Government): five thousand dollars ($5,000);

 

		·	Next (second) calendar year: ten thousand dollars ($10,000);

 

		·	Next (third) calendar year: twenty thousand dollars ($20,000);

 

		·	Next (fourth) calendar year: forty thousand dollars ($40,000);

 

		·	Next (fifth) calendar year and every calendar year thereafter: fifty thousand dollars ($50,000);

 

6.4a     No Double MARS: If LICENSEE
pays to REGENTS a minimum annual royalty in the performance of OTHER RELATED LICENSE AGREEMENT, then LICENSEE will subtract such
payments from LICENSEE’s payment to REGENTS of minimum annual royalties in the performance of this AGREEMENT.

 

6.5          Sales
Outside US:

 

6.5a     Charges: EARNED
ROYALTIES on NET SALES PRICE received in any country outside the U.S. will not be reduced by any taxes, fees or other charges imposed
by the government of such country except those taxes, fees, and charges allowed under the provisions of the Definition of NET SALES
PRICE as described in this AGREEMENT. LICENSEE also will be responsible for all bank transfer charges.

 

6.5b     Conversion:
When LICENSED PRODUCT or LICENSED METHOD is SOLD for monies other than U.S. dollars, the EARNED ROYALTIES and any other consideration
due to REGENTS will first be determined in the foreign currency of the country in which such LICENSED PRODUCTS or LICENSED METHOD
were SOLD or other consideration was received and then converted into equivalent U.S. dollars. The exchange rate will be the average
exchange rate quoted in the Wall Street Journal during the last thirty (30) days of the reporting period.

 

6.6          Patent
Expiration or Termination: In the event that any patent, patent application, or any claim thereof included within PATENT RIGHTS
expires or is held invalid in a final decision by a court of competent jurisdiction and last resort and from which no appeal has
or can be taken, all obligation to pay royalties based on such patent, patent application, or claim or any claim patentably indistinct
therefrom will cease as of the date of such final decision. However, LICENSEE is not relieved from paying any royalties that accrued
before such final decision, and LICENSEE is obligated to pay the full amount of royalties due hereunder.

 

    	Page 11 of 34

    	 

    

  

6.7          U.S.
Government Obligation: No royalties will be paid or collected on LICENSED PRODUCT or LICENSED METHOD distributed to or used
by the U.S. Government. LICENSEE and its SUBLICENSEES agree to reduce the amount charged for LICENSED PRODUCT or LICENSED METHOD
distributed to the U.S. Government by an amount equal to the royalty for such LICENSED PRODUCT or LICENSED METHOD otherwise due
REGENTS.

 

7.           DUE
DILIGENCE

 

7.1          Obligation:
Upon execution of this AGREEMENT, LICENSEE will diligently proceed with the development, manufacture, government approval, marketing
and SALE of LICENSED PRODUCT and LICENSED METHOD in quantities sufficient to meet the market demands.

 

7.2          Performance
Metrics: LICENSEE specifically commits, in accordance with the obligation stated in paragraph 7.1, to achieving the following
objectives:

 

		·	By 2009 December 31: First beta unit of third generation LICENSED PRODUCCT (that must include active hip actuation) shipped
to a potential customer. LICENSEE will send REGENTS a letter from LICENSEE’s customer that confirms the completion of this
objective;

 

		·	By 2010 December 31: First commercial order of third generation LICENSED PRODUCT (that must include active hip actuation).
LICENSEE will send REGENTS a letter from LICENCEE’s outside accountants that confirms the completion of this objective;
and

 

		·	By 2011 December 31: First commercial shipment of third generation LICENSED PRODUCT (that must include active hip actuation).
LICENSEE will send REGENTS a letter from LICENSEE’s outside accountants that confirms the completion of this objective.

 

7.3          Failure
to Perform: If LICENSEE is unable to meet any of it due diligence obligations as set forth in the Paragraph above, then REGENTS
may notify LICENSEE of its failure to perform.

 

7.3a     If REGENTS gives such
written notice to LICENSEE, then LICENSEE may extend the target date of any diligence obligation for an additional six (6) months
upon payment to REGENTS of an additional $5,000. Additional extensions may be granted only by mutual written agreement of the parties
to this AGREEMENT. Such extension fees are in addition to all other payments by LICENSEE to REGENTS pursuant to this AGREEMENT.

 

    	Page 12 of 34

    	 

    

 

7.3b     If LICENSEE opts not to
extend the obligation or fails to meet it by the extended target date, then REGENTS will have the right and option either to terminate
this AGREEMENT or to reduce LICENSEE’s exclusive license to a non-exclusive, royalty-bearing license. To exercise either
the right to terminate this AGREEMENT or to reduce the license to a non-exclusive license for lack of diligence as specified in
this Due Diligence Article, REGENTS will give LICENSEE written notice of the deficiency. After receiving notice, LICENSEE will
have sixty (60) days to cure the deficiency or to request arbitration. If REGENTS has not received a written request for arbitration
or satisfactory tangible evidence that the deficiency has been cured by the end of the sixty (60)-day period, then REGENTS may,
at its option, either terminate the AGREEMENT or reduce LICENSEE’s exclusive license to a non-exclusive license by giving
written notice to LICENSEE.

 

7.3c     This right to terminate
the AGREEMENT or reduce LICENSEE’s exclusive license to a non-exclusive license, if exercised will (a) supersede the rights
granted in the Grant of License, and Grant of Sublicense Article in this AGREEMENT, and (b) be REGENTS’s sole remedy for
breach of due diligence obligations.

 

7.4          Arbitration:
At the request of either party, any controversy or claim arising out of or relating to the diligence provisions of this Due Diligence
Article will be settled by arbitration conducted in San Francisco, CA in accordance with the then current Licensing Agreement Arbitration
Rules of the American Arbitration Association. Judgment upon the award rendered by the arbitrator(s) will be binding on the parties
and may be entered by either party in the court or forum having jurisdiction. In determination of due diligence, the arbitrator
may determine solely the issues of fact or law with respect to termination of LICENSEE’s rights under this AGREEMENT but
will not have the authority to award monetary damages or grant equitable relief.

 

8.           COMMERCIALIZATION,
PROGRESS AND ROYALTY REPORTS

 

8.1          Report
of Commercialization Plan: LICENSEE represents that the marketing overview and financial forecast provided to REGENTS are,
as of the EFFECTIVE DATE of this AGREEMENT, consistent with the equivalent information contained in LICENSEE’s business plan
that LICENSEE has presented to its Board of Directors and to entities that have or may invest capital in LICENSEE.

 

8.2          Progress
Reports: In order to enable REGENTS to assess LICENSEE’s general progress on the development of LICENSED PRODUCT and
also determine whether or not LICENSEE has met its diligence obligations as set forth in this AGREEMENT, beginning on February
28 in the year following the year in which this AGREEMENT is executed, and semi-annually thereafter until the first SALE of each
LICENSED PRODUCT, LICENSEE will submit to REGENTS a progress report as described hereunder covering activities by LICENSEE and
its SUBLICENSEES related to the development, testing, government approval, and marketing of all LICENSED PRODUCT (“PROGESS
REPORT”).

 

8.3          Contents
of Progress Reports: Each PROGRESS REPORT submitted by LICENSEE to REGENTS will include, but is not limited to, a detailed
summary of the following topics:

 

		·	Summary of work completed and in progress;

 

    	Page 13 of 34

    	 

    

 

		·	Summary of actual and anticipated events and milestones;

 

		·	The date of first SALE, if any, of LICENSED PRODUCT; and

 

		·	Activities of SUBLICENSEES if any, including any change in their large/small entity status (as defined in 15 USC §632).

 

8.4          First
Sale: LICENSEE also will report to REGENTS the date of first SALE of each LICENSED PRODUCT in each country where PATENT RIGHTS
exist in the PROGRESS REPORT for the period in which such first SALE occurred.

 

8.5          Royalty
Reports: After the first SALE of LICENSED PRODUCT, LICENSEE will provide semi-annually royalty reports (“ROYALTY REPORT”)
to REGENTS on or before each February 28 and August 31 of each year.

 

8.6          Contents
of Royalty Reports: Each such ROYALTY REPORT will cover the most recently completed reporting period and will include, but
not be limited to, the following:

 

8.6a     Pricing: The gross
invoice prices of LICENSED PRODUCT that are SOLD by LICENSEE and its SUBLICENSEES;

 

8.6b     Revenue: NET SALES
PRICE of LICENSED PRODUCT that is SOLD by LICENSEE and its SUBLICENSEES;

 

8.6c     Volume: The quantity
of LICENSED PRODUCT manufactured and SOLD by LICENSEE and its SUBLICENSEES;

 

8.6d     Royalty: The EARNED
ROYALTIES due REGENTS, in U.S. dollars, payable hereunder with respect to NET SALES PRICE of LICENSED PRODUCT that is SOLD by LICENSEE
and its SUBLICENSEES;

 

8.6e     Calculations: The
method used to calculate EARNED ROYALTY, specifying all deductions taken and the dollar amount of each such deduction as well as
the exchange rates used, if any;

 

8.6f     Non-cash Considerations:
The amount of the cash and the amount of the cash equivalent of the non-cash consideration as provided for in this AGREEMENT, including
the method used to calculate the non-cash consideration; and

 

8.6g     Sublicenses: The
name and address of new SUBLICENSEES and their large/small entity status (as defined by 15 USC §632) along with a summary
of the material terms of each new sublicensing agreement consummated.

 

8.7          No
Sale: If LICENSED PRODUCT has not been SOLD during any reporting period after the first SALE of LICENSED PRODUCT, then the
ROYALTY REPORT for that reporting period will contain a statement to this effect.

 

    	Page 14 of 34

    	 

    

  

9.           BOOKS
AND RECORDS

 

9.1          Obligation:
LICENSEE will keep books and records accurately showing all payments due to REGENTS and all LICENSED PRODUCT manufactured, used,
SOLD, offered for SALE, distributed, imported, and/or otherwise exploited under the terms of this AGREEMENT. Such books and records
will be preserved for at least five (5) years after the date of the payment to which they pertain and will be open to examination
by representatives or agents of REGENTS at reasonable times to determine their accuracy and assess the LICENSEE’s compliance
with the terms of this AGREEMENT.

 

9.2          Costs:
The fees and expenses of representatives or agents of REGENTS that perform the examination will be borne by REGENTS. However, if
any error in royalties of more than five percent (5%) of the total royalties due for any year is discovered or any other material
term of this AGREEMENT is discovered to have been breached, then LICENSEE will bear the cost of the examination. LICENSEE will
remit any underpayment to REGENTS within thirty (30) days of the examination result.

 

10.         LIFE
OF THE AGREEMENT

 

10.1        Duration:
Unless otherwise terminated by operation of law or by acts of the parties in accordance with the terms of this AGREEMENT, this
AGREEMENT will remain in effect in each country from the EFFECTIVE DATE until the expiration or abandonment of the last of the
PATENT RIGHTS licensed hereunder in such country.

 

10.2        Surviving
Rights: Any termination or expiration of this AGREEMENT will not affect the rights and obligations set forth in the following
Paragraphs and Articles of this AGREEMENT:

 

·    Article
2                 Definition

 

·    Article
4                 Grant of Sublicenses

 

·    Article
9                 Books and Records

 

·    Article
10                Life of Agreement

 

·    Article
12               Disposition of Products

 

·    Article
14               Use of Names and Trademarks

 

·    Article
15               Patent Prosecution and Maintenance

 

·    Article
17               Warranty and Liability

 

·    Article
18               Indemnification

 

·    Article
19                Confidentiality

 

    	Page 15 of 34

    	 

    

  

·    Article
20                Notices

 

		·	Paragraph 21.2         Late Payments

 

·    Article
22                Governing Laws; Venue; and Attorneys’ Fees

 

10.3       No
Relief: The termination or expiration of this AGREEMENT (a) will not relieve LICENSEE of its obligation to make any payments
pursuant to this AGREEMENT that are owed to REGENTS at the time of such termination or expiration, (b) will not impair any accrued
right of REGENTS including the right to receive EARNED ROYALTIES and other fees in accordance with this AGREEMENT, and (c) will
not relieve any obligation, of either party to the other party, that was established prior to such termination or expiration.

 

10.4       Bankruptcy:
This AGREEMENT will automatically terminate without the obligation to provide any notice as set forth in this AGREEMENT upon the
filing of a petition for relief under the U.S. Bankruptcy Code by or against the LICENSEE as a debtor or alleged debtor.

 

11.         TERMINATION

 

11.1       Termination
by REGENTS: If LICENSEE violates or fails to perform any term of this AGREEMENT, then REGENTS may give written notice of such
default (“NOTICE OF DEFAULT”) to LICENSEE. If LICENSEE fails to repair such default within sixty (60) days after
the date such notice takes effect, then REGENTS will have the right to immediately terminate this AGREEMENT and the licenses hereunder
by providing a written notice of termination (“NOTICE OF TERMINATION”) to LICENSEE.

 

11.2       Termination
by Action: This AGREEMENT will terminate immediately if LICENSEE files a claim, including in any way, the assertion that any
portion of PATENT RIGHTS is invalid or unenforceable where the filing is by the LICENSEE, a third party on behalf of the LICENSEE,
or a third party at the written urging of the LICENSEE.

 

11.3       Termination
by LICENSEE: LICENSEE has the right at any time to terminate this AGREEMENT by providing a NOTICE OF TERMINATION to REGENTS.
Moreover, LICENSEE is entitled to terminate its rights under PATENT RIGHTS on a country-by-country basis by giving notice in writing
to REGENTS. The termination of this AGREEMENT will be effective no earlier than ninety (90) days from the effective date of such
notice.

 

12.         DISPOSITION
OF PRODUCTS UPON TERMINATION

 

12.1       Termination:
Within a period of one hundred and twenty (120) days after the date of termination, LICENSEE can complete any partially made or
rendered LICENSED PRODUCT, and SELL all previously made or partially made LICENSED PRODUCT, provided, however, that the SALE of
such LICENSED PRODUCT is subject to the terms of this AGREEMENT including, but not limited to, the payment of EARNED ROYALTIES
at the times provided herein and the rendering of ROYALTY REPORTS in connection therewith. LICENSEE cannot otherwise make, SELL,
offer for SALE, distribute or import LICENSED PRODUCT, or practice the LICENSED METHOD after the date of termination.

 

    	Page 16 of 34

    	 

    

  

12.2        Expiration:
If applicable PATENT RIGHTS existed at the time of any making, SALE, offer for SALE, distribution or import of a LICENSED PRODUCT,
then EARNED ROYALTIES will be paid at the times provided herein and ROYALTY REPORTS will be rendered in connection therewith, notwithstanding
the absence of applicable PATENT RIGHTS with respect to such LICENSED PRODUCT at any later time. Otherwise, no EARNED ROYALTIES
will be paid on such product.

 

13.         PATENT
MARKING

 

13.1        US:
LICENSEE agrees to mark LICENSED PRODUCT (or their containers or labels) made, SOLD, licensed or otherwise disposed of by LICENSEE
in the U.S. under the license granted in this AGREEMENT (a) with the words “Patent Pending” prior to the issuance of
patents under PATENT RIGHTS, and (b) with the patent numbers of the PATENT RIGHTS following the issuance in the U.S. of one or
more patents under PATENT RIGHTS.

 

13.2        International:
All LICENSED PRODUCT shipped to, manufactured, or SOLD in countries outside of the U.S. will be marked in such manner as to conform
to the patent laws and practice of such countries.

 

14.         USE
OF NAMES AND TRADEMARK

 

14.1        Obligations:
Except as specified in the Metric Exception Paragraph of the Confidentiality Section of this AGREEMENT, nothing contained in this
AGREEMENT will be construed as conferring any right to either party to use in advertising, publicity, or other promotional activities
any name, trade name, trademark, or other designation of the other party (including a contraction, abbreviation or simulation of
any of the foregoing). LICENSEE is expressly prohibited from using the name “The Regents of the University of California”
or the name of any campus of the University of California in advertising, publicity, or other promotional activities unless written
consent is obtained by LICENSEE from REGENTS to do so.

 

14.2        Exceptions:
Notwithstanding the foregoing, LICENSEE can provide a copy of this AGREEMENT to investors and potential investors to the extent
allowed by law.

 

15.         PATENT
PROSECUTION AND MAINTENANCE

 

15.1        Obligations:
Subject to the limitations set forth in Paragraph 15.1a, LICENSEE will diligently prosecute and maintain the U.S. and foreign
patents and patent applications comprising the PATENT RIGHTS using counsel of its choice (“LICENSEE PATENT COUNSEL”)
provided that the continued use of such counsel at any point in the patent prosecution process of PATENT RIGHTS is subject to the
approval of REGENTS. If REGENTS rejects three (3) of LICENSEE’s choices of prosecution counsel, then
LICENSEE can select new prosecution counsel without REGENTS’ consent.

 

    	Page 17 of 34

    	 

    

 

15.1a     Deliberate
Prosecution Unfavorable to REGENTS: As REGENTS is the owner of PATENT RIGHTS, REGENTS wants to obtain the optimal breadth, depth
and overall comprehensiveness of valid, enforceable PATENT CLAIMS. Accordingly, at any time in the patent prosecution of PATENT
RIGHTS, if REGENTS believes that LICENSEE or LICENSEE PATENT COUNSEL is deliberately not attempting to obtain the optimal breadth,
depth and overall comprehensiveness of valid, enforceable PATENT CLAIMS, then LICENSEE will enable REGENTS to take control of patent
prosecution of PATENT RIGHTS and replace LICENSEE PATENT COUNSEL with REGENTS’ choice of patent counsel (if REGENTS so desires).

 

15.2       Interaction:
LICENSEE and LICENSEE PATENT COUNSEL will promptly (and sufficiently in advance of any deadlines to be able to comment)
provide REGENTS (both REGENTS’ representative as well as any inventors point of contact as described below) with copies
of all relevant documentation (“PATENT DOCUMENTATION”) so that REGENTS will be informed and apprised
of the continuing prosecution. REGENTS agree to keep PATENT DOCUMENTATION confidential in accordance with Confidentiality
Article of this AGREEMENT. REGENTS and its patent counsel have the right to consult with LICENSEE PATENT COUNSEL.
REGENTS agrees to designate one of the named inventors of INVENTIONS who is an employee of REGENTS as the inventors’
point of contact with LICENSEE PATENT COUNSEL subject to agreement with the inventors. The inventors’ point of contact will
provide detailed input to LICENSEE PATENT COUNSEL subject to the approval of REGENTS’ representative who will be copied
or included in all communications.

 

15.3       Comments:
REGENTS can comment on PATENT DOCUMENTATION sufficiently in advance of any initial deadline for filing a response, provided,
however, if REGENTS has not commented upon PATENT DOCUMENTATION in reasonable time for LICENSEE to sufficiently integrate
REGENTS’ comments prior to a deadline with the relevant government patent office, or if LICENSEE will act to
preserve PATENT RIGHTS, then LICENSEE is free to respond without integration of REGENTS’ comments, if
any.

 

15.4       Claims
Requirements: LICENSEE will amend any patent application to include claims required by REGENTS.

 

15.5       Foreign
Filing Request: At LICENSEE option, and if available, LICENSEE will file, prosecute, and maintain patent applications
and patents included under PATENT RIGHTS in foreign countries. LICENSEE will require LICENSEE PATENT COUNSEL to file Patent Cooperation
Treaty applications at the time of filing the U.S. non-provisional applications. If LICENSEE elects to file, prosecute, and maintain
such patents, it will follow the procedure set out in Paragraphs 15.1, 15.2, 15.3 and15.4 for such foreign activities. LICENSEE
will notify REGENTS within fifteen (15) months of the filing of the corresponding U.S. patent application of its election
to file foreign counterpart patent applications. This notice concerning foreign filing will be in writing and will identify the
countries desired. The absence of such a notice from LICENSEE to REGENTS within the fifteen (15) month period will be considered
an election by LICENSEE not to request LICENSEE PATENT COUNSEL to secure foreign PATENT RIGHTS on LICENSEE’s behalf.
REGENTS has the right to file patent applications at its own expense in any country that LICENSEE does not include in its list
of desired countries, and such patent applications and resultant patents, if any, will not be included in the licenses granted
hereunder. LICENSEE will cooperate in facilitating such REGENTS’ filings.

 

    	Page 18 of 34

    	 

    

  

15.6       Costs:
LICENSEE will pay all costs of obtaining patentability opinions, preparing, filing, prosecuting in whatsoever manner,
and maintaining all U.S. and corresponding foreign patent applications and resulting patents specified under PATENT RIGHTS (“PATENT
PROSECUTION COSTS”), including, but not limited to, PATENT PROSECUTION COSTS incurred by REGENTS prior to the execution
of this AGREEMENT as well as interferences, oppositions, reexaminations, and reissues. LICENSEE will reimburse REGENTS for all
PATENT PROSECUTION COSTS within thirty (30) days following receipt of an itemized invoice from REGENTS for PATENT PROSECUTION COSTS.
However, if REGENTS reduces the exclusive licenses granted herein to non-exclusive licenses pursuant to the Due Diligence Article
of this AGREEMENT and REGENTS grants additional licenses, then the PATENT PROSECUTION COSTS will be divided equally among the licensed
parties from the effective date REGENTS gives written notice to LICENSEE of the reduction of LICENSEE’s exclusive license
to a non-exclusive license.

 

15.7                     Termination:
LICENSEE will pay any PATENT PROSECUTION COSTS incurred during the three (3)-month period after receipt by either party of a NOTICE
OF TERMINATION, even if the invoices for such PATENT PROSECUTION COSTS are received by REGENTS after the end of the three (3)-month
period following receipt of a NOTICE OF TERMINATION. LICENSEE may terminate its obligation to pay PATENT PROSECUTION COSTS with
respect to any particular patent application or patent under PATENT RIGHTS in any or all designated countries upon three (3)-months’
written notice to REGENTS, provided that LICENSEE enables REGENTS to take control of patent prosecution of such PATENT RIGHTS and replace LICENSEE PATENT COUNSEL with
REGENTS’ choice of patent counsel (if REGENTS so desires). REGENTS may continue the prosecution and/or maintenance of such
patent application or patent at its sole discretion and expense, provided, however, that LICENSEE will have no further rights or
licenses thereunder.

 

16.  
       PATENT INFRINGEMENT

 

16.1       Obligations:
In the event that REGENTS (to the extent of the actual knowledge of the licensing professional responsible for the administration
of this AGREEMENT) or LICENSEE learns of infringement of potential commercial significance of any patent license under this AGREEMENT,
then the knowledgeable party will provide the other with written notice of such infringement and any evidence of such infringement
available to it (“INFRINGEMENT NOTICE”). During the period in which, and in the jurisdiction where, LICENSEE
has exclusive rights under this AGREEMENT, neither REGENTS nor LICENSEE will notify a third party (including the infringer) of
infringement or put such third party on notice of the existence of any PATENT RIGHTS without first obtaining consent of the other,
which shall not be unreasonably withheld. If LICENSEE notifies a third party of infringement or puts such third party on notice
of the existence of any PATENT RIGHTS with respect to such infringement without first obtaining the written consent of REGENTS,
then REGENTS will have the right to terminate this AGREEMENT immediately without the obligation to provide early notice as set
forth in this AGREEMENT. Both REGENTS and LICENSEE will use their diligent efforts to cooperate with each other to terminate such
infringement without litigation.

 

    	Page 19 of 34

    	 

    

 

 

16.2       Licensee
Initiated Suit: If within ninety (90) days following the date that the INFRINGEMENT NOTICE takes effect, the infringing activity
of potential commercial significance by the infringer has not been abated, then LICENSEE may institute suit for patent infringement
against the infringer. REGENTS may voluntarily join such suit at its own expense, but may not thereafter commence suit against
the infringer for the acts of infringement that are the subject of LICENSEE’s suit or any judgment rendered in that suit.
LICENSEE may not join REGENTS in a suit initiated by LICENSEE without REGENTS’ prior written consent. In a suit initiated
by LICENSEE, if REGENTS is involuntarily joined other than by LICENSEE, then LICENSEE will pay any costs incurred by REGENTS arising
out of such suit, including but not limited to, any legal fees of counsel that REGENTS selects and retains to represent REGENTS
in the suit.

 

16.3       REGENTS
Initiated Suit: If within a hundred and twenty (120) days following the date that the INFRINGEMENT NOTICE takes effect (a)
the infringing activity of potential commercial significance by the infringer has not been abated, and (b) LICENSEE has not brought
suit against the infringer, then REGENTS may institute suit for patent infringement against the infringer. If REGENTS institutes
such suit, then LICENSEE may not join such suit without REGENTS’ consent and may not thereafter commence suit against the
infringer for the acts of infringement that are the subject of REGENTS’ suit or any judgment rendered in that suit. In a
suit initiated by REGENTS, if LICENSEE is involuntarily joined other than by REGENTS, then REGENTS will pay any costs incurred
by LICENSEE arising out of such suit with respect to patent infringement, patent validity, and patent enforceability, including
but not limited to, any legal fees of counsel that REGENTS selects and retains to represent LICENSEE in the suit.

 

16.4       Allocation
of Recovery: Any recovery or settlement received in connection with any suit will first be shared by REGENTS and LICENSEE equally
to cover the litigation costs each incurred, and next will be paid to REGENTS or LICENSEE to cover any litigation costs that either
party incurred in excess of the litigation costs of the other. Any recovery in excess of litigation costs will be shared between
LICENSEE and REGENTS as follows:

 

16.4a  
  In any suit initiated by REGENTS, any recovery in excess of litigation costs will belong to REGENTS.

 

16.4b   In
any suit initiated by LICENSEE, any recovery in excess of litigation costs will be shared between LICENSEE and REGENTS as
follows:

 

i         If
REGENTS joins the suit, any recovery in excess of litigation costs will be shared in proportion to the costs incurred by each party,
but in no event will REGENTS’ proportion be less than ten percent (10%);

 

ii         If
REGENTS does not join the suit, any recovery in excess of litigation costs will belong to LICENSEE.

 

16.5       Binding:
REGENTS and LICENSEE agree to be bound by all determinations of patent infringement, validity, and enforceability (but no other
issue) resolved by any adjudicated judgment in a suit brought in compliance with this Article.

 

16.6       Compliance:
Any agreement made by the LICENSEE for purposes of settling litigation or other dispute will comply with the requirements of the
Sublicense Article of this AGREEMENT.

 

    	Page 20 of 34

    	 

    

 

16.7       Cooperation:
Each party will cooperate with the other in litigation proceedings instituted hereunder but at the expense of the party who initiated
the suit (unless such suit is being jointly prosecuted by the parties).

 

16.8       Control:
The party bringing the suit will control any litigation proceedings, except that REGENTS may be represented by counsel of its choice
in any suit brought by LICENSEE.

 

17.       
 WARRANTY AND LIABILITY

 

17.1       REGENTS
warrants to LICENSEE that REGENTS has the lawful right to grant this license.

 

17.2       Except
as expressly set forth in Paragraph 17.1 this AGREEMENT, the licenses and the associated INVENTION, PATENT RIGHTS, LICENSED PRODUCTS,
and LICENSED METHODS are provided by REGENTS WITHOUT WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR ANY OTHER
WARRANTY OF ANY KIND, EITHER EXPRESS OR IMPLIED. REGENTS MAKES NO EXPRESS OR IMPLLIED REPRESENTATION OR WARRANTY THAT THE INVENTION,
PATENT RIGHTS, LICENSE PRODUCTS, OR LICENSE METHODS WILL NOT INFRINGE ANY PATENT, COPYRIGHT, TRADEMARK OR OTHER RIGHTS.

 

17.3       REGENTS
WILL NOT BE LIABLE FOR ANY LOST PROFITS, COSTS OF PROCURING SUBSTITUTE GOODS OR SERVICES, LOST BUSINESS, ENHANCE DAMAGES FOR INTELLECTUAL
PROPERTY INFRINGEMENT, OF FOR ANY INDIRECT, INCIDENTAL, CONSEQUENTIAL, PUNITIVE, OR OTHER SPECIAL DAMAGES SUFFERED BY LICENSEE,
SUBLICENSEES, JOINT VENTURES, OR AFFILIATES ARISING OUT OF OR RELATED TO THIS AGREEMENT FOR ALL CAUSES OF ACTION OF ANY KIND (INCLUDING
TORT, CONTRACT, NEGLIGENCE, STRICT LIABILITY AND BREACH OF WARRANTY) EVEN IF REGENTS HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH
DAMAGES.

 

17.4       Nothing
is this AGREEMENT is or will be construed as:

 

17.4a     A
warranty or representation by REGENTS as to the validity, enforceability, or scope of any PATENT RIGHTS; or

 

17.4b     A
warranty or representation that anything made, used, SOLD, or otherwise exploited under any license granted in this AGREEMENT is
or will be free from infringement of patents, copyrights, or other rights of third parties; or

 

17.4c     An
obligation to bring or prosecute actions or suits against third parties for patent infringement except as provided in the Patent
Infringement Article of this AGREEMENT; or

 

    	Page 21 of 34

    	 

    

 

 

17.4d     Conferring
by implication, estoppel, or otherwise any license or rights under any patents or other rights of REGENTS other than PATENT RIGHTS,
regardless of whether such patents are dominant or subordinate to PATENT RIGHTS; or

 

17.4e     An
obligation to furnish any NEW DEVELOPMENTS, know-how, technology, or technological information not provided in PATENT RIGHTS.

 

18.     
    INDEMNIFICATION

 

18.1       Requirements:
LICENSEE will, and will require its SUBLICENSEES to, indemnify, hold harmless, and defend REGENTS and its officers, employees,
and agents, the sponsors of the research that led to the INVENTION, the inventors of any invention claimed in patents or patent
applications under PATENT RIGHTS (including the LICENSED PRODUCT, and LICENSED METHODS contemplated thereunder) and inventors’
employers against any and all claims, suits, losses, damage, costs, fees, and expenses resulting from, or arising out of, the exercise
of this license or any sublicense. This indemnification will include, but will not be limited to, any product liability. If REGENTS,
in its sole discretion, believes that there will be a conflict of interest or REGENTS will not otherwise be adequately represented
by counsel chosen by LICENSEE to defend REGENTS in accordance with this Paragraph, then REGENTS may retain counsel of its choice
to represent it, and LICENSEE will pay all expenses for such representation.

 

18.2       Insurance:
During the term of this AGREEMENT and for three (3) years following its termination or expiration, LICENSEE, at its sole cost and
expense, will insure its activities in connection with any work performed hereunder and will obtain and maintain insurance as follows:

 

18.2a     Upon
EFFECTIVE DATE, Commercial Form General Liability Insurance (contractual liability included) with limits as follows:

 

	  i.	 	Each Occurrence	 	$	1,000,000	 
	 	 	 	 	 	 	 
	 ii.	 	Products/Completed Operations Aggregate	 	$	1,000,000	 
	 	 	 	 	 	 	 
	iii.	 	Personal and Advertising Injury	 	$	1,000,000	 
	 	 	 	 	 	 	 
	iv.	 	General Aggregate	 	$	1,000,000	 

 

18.2b     If
LICENSEE offers a LICENSE PRODUCT that is a medical device, then prior to first SALE of such medical device, Commercial Form General
Liability Insurance (contractual liability included) with limits as follows:

 

	  i.	 	Each Occurrence	 	$	5,000,000	 
	 	 	 	 	 	 	 
	 ii.	 	Products/Completed Operations Aggregate	 	$	10,000,000	 
	 	 	 	 	 	 	 
	iii.	 	Personal and Advertising Injury	 	$	5,000,000	 
	 	 	 	 	 	 	 
	iv.	 	General Aggregate	 	$	10,000,000	 

 

    	Page 22 of 34

    	 

    

 

 

18.2c     The
coverage and limits referred to in the Subparagraph above will not in any way limit the liability of LICENSEE.

 

18.2d     LICENSEE
will furnish REGENTS with certificates of insurance evidencing compliance with all requirements. Such certificates will:

 

i.          Provide
for thirty (30) days’ advance written notice to REGENTS of any modification;

 

ii.         Indicate
that REGENTS has been endorsed as an additional insured under the coverage described above; and

 

iii.        Include
a provision that the coverage will be primary and will not participate with, nor will be excess over, any valid and collectable
insurance or program of self-insurance maintained by REGENTS.

 

18.3       Notification:
REGENTS will promptly notify LICENSEE in writing of any claim or suit brought against REGENTS for which REGENTS intends to invoke
the provisions of this Indemnification Article. LICENSEE will keep REGENTS informed of its defense of any claims pursuant to this
Indemnification Article.

 

19.         CONFIDENTIALITY

 

19.1       Obligation:
LICENSEE and REGENTS will treat and maintain the other party’s proprietary business, patent prosecution, software, engineering
drawings, process and technical information, and other proprietary information, including the negotiated terms of this AGREEMENT,
PROGRESS REPORTS, ROYALTY REPORTS and PATENT DOCUMENTATION (“CONFIDENTIAL INFORMATION”) in confidence using
at least the same degree of care as the receiving party uses to protect its own proprietary information of a like nature.

 

19.2       Disclosure:
LICENSEE and REGENTS may use and disclose CONFIDENTIAL INFORMATION to their employees, agents, consultants, contractors, and, in
the case of LICENSEE, its SUBLICENSEES, provided that such parties are bound by a like duty of confidentiality as that found in
this Confidentiality Article. Notwithstanding anything to the contrary contained in this AGREEMENT, REGENTS may release this AGREEMENT,
including any terms contained herein, and information regarding royalty payments or other income received in connection with this
AGREEMENT to the inventors, senior administrative officials employed by REGENTS, and individual Regents upon their request. If
such release is made, REGENTS will request that such terms be kept in confidence in accordance with the provisions of this Confidentiality
Article.

 

19.3       Marking:
All written CONFIDENTIAL INFORMATION will be labeled or marked confidential or proprietary. If the CONFIDENTIAL INFORMATION is
orally disclosed, it will be reduced to writing or some other physically tangible form, marked and labeled as confidential or proprietary
by the disclosing party and delivered to the receiving party within thirty (30) days after the oral disclosure.

 

    	Page 23 of 34

    	 

    

  

19.4       General
Exceptions: Nothing contained herein will in any way restrict or impair the right of LICENSEE or REGENTS to use or disclose
any CONFIDENTIAL INFORMATION:

 

19.4a     That
recipient can demonstrate by written records was previously known to it prior to its disclosure by the disclosing party;

 

19.4b     That
recipient can demonstrate by written records is now, or becomes in the future, public knowledge other than through acts or omissions
of recipient;

 

19.4c     That
recipient can demonstrate by written records was lawfully obtained without restrictions on the recipient from sources independent
of the disclosing party; or

 

19.4d     That
is required to be disclosed pursuant to the California Public Records Act or other applicable law.

 

19.5       Other
Exceptions: LICENSEE or REGENTS may use or disclose CONFIDENTIAL INFORMATION that is required to be disclosed:

 

19.5a     To
a governmental entity or agency in connection with seeking any governmental or regulatory approval, governmental audit, or other
governmental requirement; or

 

19.5b     By
law, provided that the recipient uses reasonable efforts to give the party owning the CONFIDENTIAL INFORMATION sufficient notice
of such required disclosure to allow the party owning the CONFIDENTIAL INFORMATION reasonable opportunity to object to, and to
take legal action to prevent, such disclosure.

 

19.6       Inquiry
Exceptions: REGENTS also may disclose the existence of this AGREEMENT and the extent of the grant of license and sublicenses
herein to a third party that inquires whether a license to the PATENT RIGHTS is available, but REGENTS will not disclose the name
of the LICENSEE unless LICENSEE has already made such disclosure publicly.

 

19.7       Metric
Exceptions: REGENTS can publicly identify LICENSEE’s corporate name and contact information as an entity with which REGENTS
has an agreement that involves the commercialization of technology developed at the University of California, Berkeley; however
this exception does not cover other information about this AGREEMENT, including INVENTIONS and INVENTORS, when used in association
with LICENSEE’s name.

 

19.8       Termination:
Upon termination of this AGREEMENT, LICENSEE and REGENTS will destroy or return any of the disclosing party’s CONFIDENTIAL
INFORMATION in its possession within fifteen (15) days following the termination of this AGREEMENT, LICENSEE and REGENTS will provide
each other, within thirty (30) days following termination, with written notice that such CONFIDENTIAL INFORMATION has been returned
or destroyed. Each party, may, however, retain one copy of such CONFIDENTIAL INFORMATION for archival purposes in non-working files.

 

    	Page 24 of 34

    	 

    

  

19.9       Expiration:
The terms of this Confidentiality Article will expire in five (5) years from the effective date of termination of this AGREEMENT.

 

20.         NOTICES

 

20.1       Addresses:
Any notice or payment that is required to be given to either party will be deemed to have been property given when done in writing
and deposited in the U.S. mail, registered or certified, addressed as follows or to another address as designated in writing by
the party changing its address:

 

20.1a     To LICENSEE:

 

		·	Berkeley ExoTech, Inc.

 

		·	2131 University Ave. #428

 

		·	Berkeley, CA 94704

 

		·	Telephone: 510-984-1761

 

		·	Facsimile: 510-277-1406

 

		·	Email: info@BerkeleyBionics.com

 

		·	Attention: COO

 

		20.1b	       To REGENTS:

 

		·	Office of Technology Licensing

 

		·	2150 Shattuck Avenue, Suite 510

 

		·	Berkeley, CA 94720-1620

 

		·	Attn: Director (REGENTS Case Number B07-128, B08-119, B08-125, B08-141)

 

20.2       Effective
Date: Any such properly given notice or payment will be deemed to be effective as follows:

 

20.2a     On
the date of delivery if delivered in person;

 

20.2b     On
the date of mailing if mailed by first-class certified mail; or

 

20.2c     On
the date of mailing if mailed by any global express carrier service that requires the signature of recipient to demonstrate the
delivery of such notice or payment.

 

    	Page 25 of 34

    	 

    

  

21.         PAYMENTS

 

21.1       Payment
Method: All consideration due REGENTS will be payable in U.S. dollars. LICENSEE will make all payments to REGENTS under this
AGREEMENT by check payable to “The Regents of the University of California” and forward it to REGENTS in accordance
with the Notices Article 20.

 

21.2       Late
Payments: If any monies owed to REGENTS are not received by REGENTS when due, then LICENSEE will pay to REGENTS interest at
a rate of ten percent (10%) simple interest per annum. Interest will be calculated from the date payment was due until actually
received by REGENTS. Accrual of interest will be in addition to, and not in lieu of, enforcement of any other rights of REGENTS
due to late payment. Acceptance by REGENTS of any late payment from LICENSEE under this Article will in no way affect the provision
of the Waiver Paragraph of this AGREEMENT.

 

21.3       Foreign
Money Restrictions: Notwithstanding the provisions of the Force Majeure Paragraph of this AGREEMENT, if at any time legal restrictions
prevent prompt remittance of any monies or other consideration owed to REGENTS by the LICENSEE with respect to any country where
a sublicense is issued or a LICENSED PRODUCT or LICENSED METHOD is SOLD, then LICENSEE will convert the amount owed to REGENTS
into U.S. dollars and will pay REGENTS directly from another source of funds in order to remit the entire amount owed to REGENTS.

 

22.         GOVERNING
LAWS; VENUE; ATTORNEYS’ FEES

 

22.1       THIS
AGREEMENT WILL BE INTERPRETED AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF CALIFORNIA, excluding any choice of law
rules that would direct the application of the laws of another jurisdiction, but the scope and validity of any patent or patent
application will be governed by the applicable laws of the country of such patent or patent application.

 

22.2       Any
legal action related to this AGREEMENT will be conducted in San Francisco, California.

 

22.3       The
prevailing party in any suit related to this AGREEMENT will be entitled to recover its reasonable attorneys’ fees in addition
to its costs and necessary disbursements.

 

23.         GOVERNMENT
APPROVAL OR REGISTRATION

 

23.1       Obligation:
If the law of any nation requires that this AGREEMENT or any associated transaction be either approved or registered with any government
agency, then LICENSEE will assume all legal obligations to do so. LICENSEE will notify REGENTS if it becomes aware that this AGREEMENT
is subject to a U.S. or foreign government reporting or approval requirement.

 

23.2       Costs:
LICENSEE will make all necessary filings and pay all costs including fees, penalties, and other out-of-pocket costs associated
with such reporting or approval process.

 

    	Page 26 of 34

    	 

    

  

24.         GOVERNMENT
EXPORT AND IMPORT LAWS

 

24.1       LICENSEE
will comply with all applicable international, national, state, regional, and local laws and regulations in performing its obligations
hereunder and in its use, manufacture, SALE, or import of the LICENSED PRODUCT or practice of the LICENSED METHOD.

 

24.2       LICENSEE
will observe all applicable U.S. and foreign laws with respect to the transfer or provision of LICENSED PRODUCT and related technical
data to foreign countries, including, without limitation, the International Traffic in Arms Regulations (ITAR) and the Export Administration
Regulations.

 

24.3       When
LICENSED PRODUCT is made outside the particular country in which such LICENSED PRODUCT is used, SOLD, or otherwise exploited, then
LICENSEE will manufacture LICENSED PRODUCT or practice LICENSED METHOD in compliance with applicable government importation laws
and regulations of the particular country.

 

25.         MISCELLANEOUS

 

25.1       Assignment:

 

25.1a     LICENSEE:
This AGREEMENT is personal to LICENSEE and assignable by LICENSEE only with the written consent of REGENTS, except that LICENSEE
may freely assign this AGREEMENT to an acquirer of all or substantially all of LICENSEE’s stock, assets or business.

 

25.1b     REGENTS:
This AGREEMENT is binding upon and will inure to the benefit of REGENTS, its successors and assigns.

 

25.2       Waiver:

 

25.2a     No
waiver by either party of any breach or default of any of the duties, obligations, or agreements contained herein will be deemed
a waiver as to any subsequent and/or similar breach or default.

 

25.2bNo waiver will be valid
or binding upon the parties unless made in writing and signed by a duly authorized officer of each party.

 

25.3       Force
Majeure

 

25.3a     Responsibility:
Except for LICENSEE’s obligation to make any payments to REGENTS hereunder, the parties will not be responsible for any failure
to perform due to the occurrence of any events beyond their reasonable control which render their performance impossible or onerous,
including, but not limited to: accidents (environmental, toxic spill, etc.); acts of God; biological or nuclear incidents; casualties;
earthquakes; fires, floods, governmental acts, orders or restrictions; inability to obtain suitable and sufficient labor, transportation,
fuel and materials; local, national, or state emergency; power failure and power outages; acts of terrorism; strike; and war.

 

    	Page 27 of 34

    	 

    

  

25.3b     Termination:
Either party to this AGREEMENT, however, will have the right to terminate this AGREEMENT upon thirty (30) days’ prior written
notice if either party is unable to fulfill its obligations under this AGREEMENT due to any of the causes specified in the Paragraph
above for a period of one (1) year.

 

25.4       Severability:
If any of the provisions contained in this AGREEMENT are held to be invalid, illegal, or unenforceable in any respect, such invalidity,
illegality, or unenforceability will not affect any other provisions hereof, and this AGREEMENT will be construed as if such invalid
or illegal or unenforceable provisions had never been contained herein.

 

25.5       Scope:
This AGREEMENT embodies the entire understanding of the parties and supersedes all previous communications, representations, or
understandings, whether oral or written between the parties relating to the subject matter hereof.

 

25.6       Amendments:
No amendment or modification of this AGREEMENT will be valid or binding upon the parties unless made in writing and signed on behalf
of each party.

 

25.7       Parties:
No provisions of this Agreement are intended or will be construed to confer upon or give to any person or entity other than REGENTS
and LICENSEE any rights, remedies, or other benefits under, or by reason of, this AGREEMENT.

 

25.8       Independence:
In performing their respective duties under this AGREEMENT, each of the parties will be operating as an independent contractor.
Nothing contained herein will in any way constitute any association, partnership, or joint venture between the parties hereto,
or be construed to evidence the intention of the parties to establish any such relationship. Neither party will have the power
to bind the other party or incur obligations on the other party’s behalf without the other party’s written consent.

 

25.9       Headings:
The headings of the sections are inserted for convenience of reference only and are not intended to affect the meaning or interpretation
of this AGREEMENT.

 

    	Page 28 of 34

    	 

    

  

In witness whereof, both REGENTS and LICENSEE
have executed this AGREEMENT, in duplicate originals, by their respective officers hereunto duly authorized, on the date and year
hereinafter written.

 

	Berkeley Bionics	 	The Regents of the University of California
	 	 	 	 	 
	By:	/s/ Nathan Harding	 	By:	/s/ Michael Cohen
	(Signature)	 	(Signature)
	 	 	 	 	 
	Name:	Nathan Harding	 	Name:	Michael Cohen
	 	 	 	 	 
	Title:	COO	 	Title:	Acting Director, OTL
	 	 	 	 	 
	Date:	July 14, 2008	 	Date:	July 7, 2008

 

    	Page 29 of 34

    	 

    

  

UNIVERSITY OF CALIFORNIA, BERKELEY

 

 

AMENDMENT #1 TO EXCLUSIVE LICENSE
AGREEMENT

 

U.C. Case Nos.: B07-128, B08-119,
B08-125, B08-14, B09-112

Agreement Number: 2009-04-0008

 

Effective May 20, 2009, THE REGENTS
OF THE UNIVERSITY OF CALIFORNIA, a California Corporation whose legal address is 1111 Franklin Street, 12th Floor, Oakland, CA
94607-5200, acting through its Office of Technology Licensing at the University of California, Berkeley, 2150 Shattuck Avenue,
Suite 510, Berkeley, CA 94720-1620 ("REGENTS"), and Berkeley Bionics, a California corporation having a principal
place of business at 2131 University Ave. #428, Berkeley, CA 94794 (“LICENSEE"),
agree to amend the Exclusive License Agreement dated June 14, 2008 ("License Agreement").

 

Amend Article 1.1 to ADD:

 

		·	1.1e Wearable Material Handling System as described in REGENTS Case Number B09-112 and PATENT
RIGHTS that was invented by Homayoon Kazerooni, Nathan Harding, Kurt Amundson, Russdon Angold, Jon Burns and Adam Zoss. 

 

Amend Article 1.2 to REPLACE WITH
THE FOLLOWING:

 

		·	1.2 LICENSEE and REGENTS jointly own the intellectual property resulting from the INVENTIONS described in Paragraphs 1.1b,
1.1c, 1.1d, and 1.1e.

 

Amend Article 1.5 to REPLACE:

 

		·	"Paragraphs 1.1b (B08-119) and 1.1c (B08-125)”
WITH "Paragraphs 1.1b (B08-119), 1.1c (B08-125), and I. 1 e (B09-1 12)" 

 

Amend Article 2.1 to ADD:

 

		·	2.le The INVENTION described in Paragraph l.le Wearable Material
Handling System, filed by, Homayoon Kazerooni, Nathan Harding, Kurt Amundson, Russdon Angold, Jon Burns and Adam Zoss. 

 

In consideration for the above addition,
LICENSEE will pay a licensee fee in the amount of three thousand dollars ($3,000) upon execution of this Amendment.

 

All other terms and
conditions in the License Agreement remain in full force and effect.

 

    	 

    	 

    

 

IN WITNESS WHEREOF, the parties hereto
have executed this agreement in duplicate originals by their duly authorized officers or representatives.

 

	THE REGENTS OF THE UNIVERSITY OF CALIFORNIA	 	BERKELEY BIONICS
	 	 	 
	Signature	/s/ Michael Cohen	 	Signature	/s/ Nathan Harding
	Michael Cohen	 	Name: Nathan Harding
	Acting Director	 	Title: C.O.O.
	 	 	 
	Date: 2009 May 21	 	Date: 5/20/2009

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00225-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00225-of-00352.parquet"}]]